Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)
Appears in 2 contracts
Sources: Agreement and Plan of Merger (Santarus Inc), Agreement and Plan of Merger (Santarus Inc)
Terms Defined Elsewhere. The following is a list of additional Other than the terms used defined in this Agreement and a reference to Exhibit B, the following terms are defined elsewhere in the Agreement, as indicated below: Additional Issuer SEC Reports Section hereof in which such term is defined: 2.7(a) Agreement Preamble Biogen Idec License Agreement Aggregate Principal Amount Section 4.7 Biogen Idec Supply Agreement 1.1 Bankruptcy and Equity Exception Section 4.7 Books and Records 2.3(a) BCA Recitals Change in Recommendation Section 2.12(f)(2) Claim Notice Section 8.3(a7.11(a) Closing Section 2.3 1.4(a) Closing Conditions Article VI Closing Date Section 2.3 1.4(a) Closing Notice Section 1.4(b) Company Preamble Company Common Stock Disclosure Schedule(s) Article III Company Fundamental Representations Section 2.8 5.1(a) Company Disclosure Schedule Article IV Leased Real Property Section 3.18(b) Company Expenses Schedule Owned Real Property Section 2.13 3.18(a) Company Indemnified Parties Property Section 8.2(a)(ii3.18(b) Contracts Company Real Property Lease Section 4.8(a3.18(b) Covered Company Related Party (PartiesSection 3.21 Company Related Party Transactions Section 3.21 Contract Property Section 3.18(e) Conversant Investor Recitals Conversant Subscription Agreement Recitals Convertible Notes Recitals Current Credit Agreement Section 8.2(a)(ii7.8(f) Damages Section 8.2(a)(i9.2(a)(i) DGCL Designated Court(s) Section 2.1 9.16 Disclosure Document Retention Period Section 2.12(f)(27.5(a) Drug Regulatory Agency Disclosure Schedule(s) Article III Effectiveness Date Section 4.25 Effective Time 7.3(a) Election Notice Section 2.2 ERISA 7.7(c) Filing Deadline Section 4.13(a7.3(a) ERISA Affiliate Final Offer Notice Section 4.13(a7.7(b) Finally Determined Financial Statements Section 8.5(b3.4(a) First Milestone Indemnified Breaches Section 2.10(e) First Milestone Payment Amount Section 2.10(e9.2(a)(i) Indemnifying Party Section 8.3(a9.2(a)(i) Instrument Initial Offer Notice Section 2.12(c7.7(b) Merger Insurance Policies Section 2.1 Merger Certificate 3.15 Interim Financial Statements Section 2.2 Merger Sub 3.4(a) Investor Indemnified Persons Section 9.2(a)(i) Investor Subscription Agreement Recitals Investor(s) Preamble Parent Preamble Parent Disclosure Schedule Investor’s Closing Conditions Article V Parent IPO Prospectus Section 7.6(a) Issuance Approval Section 2.2(b) Issuance Approval Meeting Section 7.11(a) Issuance Approval Meeting Deadline Section 7.11(a) Issuance Approval Proxy Statement Section 7.11(a) Issuer Preamble Issuer Board Section 2.2(b) Issuer Board Recommendation Section 2.2(b) Issuer Companies Recitals Issuer Disclosure Schedule(s) Article II Issuer Fundamental Representations Section 5.1(a) Issuer Indemnified Parties Persons Section 8.2(a)(i9.2(b) parties Preamble Payee Issuer Related Party Section 8.5 Payor 2.9 Issuer Related Party Transactions Section 8.5 Per Diem Taxes 2.9 Issuer SEC Reports Section 8.7(a2.7(a) Proceeding Issuer’s and Company’s Closing Conditions Article VI Latest Balance Sheet Section 4.17 Royalties 3.4(a) Material Contracts Section 2.10(h3.7(a) Second Milestone Material Permits Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)3.6
Appears in 2 contracts
Sources: Convertible Note Purchase Agreement (DiamondHead Holdings Corp.), Convertible Note Purchase Agreement (DiamondHead Holdings Corp.)
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounting Firm Section 2.4(b) Agreement Preamble Biogen Idec License Antitrust Laws Section 6.2(d) Applicable Limitation Date Section 6.4 Binder Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(a) Buyer Preamble Buyer Released Party Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a) 6.9 Closing Section 2.3 2.5 Closing Date Section 2.3 2.5 Closing Item Section 2.4(a) Closing Statement Section 2.4(a) Company Preamble Company Common Stock Employee Benefit Plan Section 2.8 3.14(a) Company Disclosure Schedule Article IV Company Proprietary Rights Section 3.10(a) Continuing Employees Section 6.13 control Section 1.1 D&O Indemnified Persons Section 6.10(a) D&O Provisions Section 6.10(a) Dispute Notice Section 2.4(b) Estimated Book Value Section 2.3 Estimated Closing Statement Section 2.3 Estimated Indebtedness Section 2.3 Estimated Statutory Surplus Section 2.3 Estimated Transaction Expenses Schedule Section 2.13 Company Indemnified 2.3 Excess Amount Section 2.4(d) Final Book Value Section 2.4(a) Final Indebtedness Section 2.4(a) Final Statutory Surplus Section 2.4(a) Final Transaction Expenses Section 2.4(a) Financial Statements Section 3.4(a) Interests Recitals Investment Guidelines Section 3.16(f)(iii) IRS Section 3.14(a) K&E Section 8.11 Key Employee Offer Letters Recitals Latest Balance Sheet Section 3.4(a) Material Contract Section 3.9(b) New Mandeville Lease Recitals New Plans Section 6.13 Non-Party Affiliates Section 6.15 Outside Date Section 7.1(c) Ordinary Course of Business Section 8.5 Party Preamble Payoff Letters Section 2.6(b)(v)(K) Policies Section 3.15 Post-Closing Representation Section 8.11 Pre-Closing Period Section 6.1(a) 15 Privacy and Information Security Policies Section 3.22(a) Privacy Agreements Section 3.22(a) Regulatory Approvals Section 6.2(a) Released Funds Section 2.4(e) Resolution Period Section 2.4(b) Review Period Section 2.4(b) R&W Insurance Policy Section 6.3(a) Seller Preamble Shortfall Amount Section 2.4(e) Stuatory Statements Section 3.4(b) Tail Policy Section 6.10(b) Transfer Taxes Section 6.5(c) Transition Services Agreement Section 2.6(b)(v)(I) Waived 280G Benefits Section 6.17 Waiving Parties Section 8.2(a)(ii) Contracts 8.11 Withholding Agent Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)2.7
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 5.07(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.03(d)(i) Book-Entry Shares Section 4.7 Books and Records 2.02(b) Capitalization Date Section 2.12(f)(23.02(a) Claim Notice Certificate of Merger Section 8.3(a1.02 Certificates Section 2.02(b) Change of Board Recommendation Section 5.03(a)(iv) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Board Recommendation Recitals Company Disclosure Schedule Article IV ARTICLE III Company Expenses Schedule Employees Section 2.13 5.07(a) Company Indemnified Parties Financial Statements Section 8.2(a)(ii3.07(a) Contracts Company Material Contract Section 4.8(a3.13(a) Covered Party (PartiesCompany Permits Section 3.05(a) Company Preferred Stock Section 8.2(a)(ii3.02(a) Damages Company Representatives Section 8.2(a)(i5.02(a) Company SEC Documents Section 3.06(a) Company Stockholder Approval Section 3.21 Confidentiality Agreement Section 5.02(c) D&O Insurance Section 5.08(c) DGCL Recitals Dispute Section 2.1 Document Retention Period 3.15(i) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.03 Effective Time Section 2.2 ERISA 1.02 Electronic Delivery Section 4.13(a8.13 Employment Practices Section 3.12(a) ERISA Affiliate Equity Plan Documents Section 4.13(a2.04(b) Finally Determined Equity Plan Stock Section 8.5(b2.04(b) First Milestone Exon-▇▇▇▇▇▇ Filing Section 2.10(e5.04(c) First Milestone Payment Export Approvals Section 3.05(e) Guarantee Section 8.15(c) Guaranteed Obligations Section 8.15(a) Guarantor Section 8.15(a) Insurance Policies Section 3.17 Intervening Event Notice Period Section 5.03(e)(i) Lease Agreement Section 3.18(c) Leased Real Property Section 3.18(c) LGPL Section 3.15(f) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.08(c) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Recitals Merger Sub Preamble Most Recent Balance Sheet Section 3.09(a)(i) New Plans Section 5.07(a) Parent Preamble Parent Disclosure Schedule Article V 401(k) Plan Section 5.07(c) Parent Indemnified Parties Representatives Section 8.2(a)(i5.02(a) parties Preamble Payee Parent Subsidiary Section 8.5 Payor 4.03(a) Parent Welfare Plan Section 8.5 Per Diem Taxes 5.07(a) Paying Agent Section 8.7(a2.02(a) Proceeding Proxy Statement Section 4.17 Royalties 1.03(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 2.10(h3.06(a) Second Milestone Section 2.10(f16 Section 5.10 Shares Recitals Significant Customer Section 3.23 Special Meeting Section 1.03(e) Second Milestone Payment Amount Superior Proposal Notice Period Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.03(d)(i) Surviving Corporation Recitals Takeover Law Section 2.1 Third Milestone 3.03(b) Termination Fee Section 2.10(g7.02(b) Third Milestone Payment Amount Unvested Cash Section 2.10(g2.04(b) WARN Act Section 3.12(e) Worker List Section 3.12(g)
Appears in 1 contract
Sources: Merger Agreement (Ariba Inc)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Recommendation Change Section hereof in which such term is defined: 6.02(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.02(c) Arbitrator Section 4.7 Books and Records 10.08(b) Assumed Option Section 2.12(f)(23.03(b) Claim Notice Base Premium Section 8.3(a7.05(d) Benefit Plan Section 4.15(b) BlueCity Holdings Limited Section 2.06 Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.02(b) Company Disclosure Schedule Article IV Group Section 9.02(h) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(e) Competing Proposal Section 8.2(a)(ii) Contracts Section 4.8(a6.02(g) Covered Party (PartiesPersons Section 7.05(a) Deposit Agreement Section 8.2(a)(ii3.05 Depositary Section 3.05 Dissenting Shareholders Section 3.06(a) Damages Dissenting Shares Section 8.2(a)(i3.06(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.03 Equity Commitment Letter Section 5.05(a) Equity Financing Section 5.05(a) Exchange Ratio Section 3.03(b) Financial Statements Section 4.06(b) HKIAC Section 10.08(b) HKIAC Rules Section 10.08(b) Indemnification Agreements Section 7.05(a) Insurance Policies Section 4.18 Intervening Event Section 6.02(e) Legal Proceeding Section 5.08 Limited Guarantee Recitals Material Contracts Section 4.16(a)(xiv) Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 3.02(a) Merger Sub Preamble Nasdaq Section 4.02(c) Non-Required Remedy Section 7.02(d) Operating Subsidiary Section 4.16(a)(xi) Parent Preamble Parent Group Section 9.02(h) Parent Termination Fee Section 9.02(f) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 PRC Subsidiaries Section 4.09(a) Proxy Statement Section 4.05 Record ADS Holders Section 6.04(a) Record Date Section 6.04(a) Registrar of Companies Section 2.03 Rollover Shareholders Recitals S▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule 13E-3 Section 6.03(a) SEC Documents Section 4.06(a) Securities Act Section 4.06(a) Share Certificates Section 3.02(b)(i) Social Insurance Section 4.15(k) Special Committee Recitals Superior Proposal Section 6.02(h) Support Agreement Recitals Surviving Company Section 2.01 Takeover Statute Section 4.23 Tax Returns Section 4.13(a) ERISA Affiliate Transaction Litigation Section 4.13(a7.08 Transactions Recitals U.S. GAAP Section 4.06(b) Finally Determined Uncertificated Shares Section 8.5(b3.02(b)(i) First Milestone VIE Contracts Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.09(c)
Appears in 1 contract
Sources: Merger Agreement (Ma Baoli)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 3.11 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.2(c)(ii) Anti-Takeover Statute Section 4.7 Books and Records 3.3(c) Antitrust Order Section 2.12(f)(25.5(d) Claim Notice Antitrust Proceeding Section 8.3(a5.5(d) Certificates Section 2.2(b) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Company Preamble Company Adverse Recommendation Change Section 5.2(c)(i) Company Board Recitals Company Board Recommendation Section 3.2(c) Company Common Stock Section 2.8 2.1(a)(i) Company Disclosure Schedule Article IV Financial Advisor Section 3.2(d) Company Expenses Schedule Financial Statements Section 2.13 3.5(b) Company Indemnified Parties Material Contract Section 8.2(a)(ii3.10(a) Contracts Section 4.8(a) Covered Party (PartiesCompany Plan(s) Section 8.2(a)(ii3.12(a) Damages Company Preferred Stock Section 8.2(a)(i3.4(a) DGCL Company Registered Intellectual Property Section 2.1 Document Retention Period 3.14(a) Company Representatives Section 2.12(f)(25.4(a) Drug Regulatory Agency Company SEC Filings Section 4.25 3.5(a) Company Shareholders Recitals Company Shareholders’ Meeting Section 5.3(a) Company Shareholder Approval Section 3.2(b) Company Subsidiary Section 2.7 D&O Insurance Section 5.9(c) Deferred Share Cash Balance Section 2.4(d) Department of State Section 1.3 Determination Notice Section 5.2(d)(i)(A) Effective Time Section 2.2 1.3 End Date Section 7.1(b) Enforceability Exception Section 3.10(b) ERISA Section 4.13(a3.12(a) ERISA Affiliate Section 4.13(a3.12(a) Finally Determined Event Section 8.5(b8.1(p) First Milestone Exchange Fund Section 2.10(e2.2(a) First Milestone Payment FCPA Section 3.21 Final Exercise Date Section 2.5 Indemnified Parties Section 5.9(a) Investments Section 3.4(f) Material Leased Real Property Section 3.17(b) Material Real Property Leases Section 3.17(b) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.9(c) Merger Section 2.1 1.1 Merger Certificate Consideration Section 2.2 2.1(a)(i) Merger Sub Preamble Notice Period Section 5.2(d)(i)(A) Owned Real Property Section 3.17(a) Parent Preamble Parent Disclosure Schedule Article V Benefit Plans Section 5.8(c) Parent Indemnified Parties Representatives Section 8.2(a)(i5.4(a) parties Party Preamble Payee Paying Agent Section 8.5 Payor 2.2(a) PBCL Recitals Proxy Date Section 8.5 Per Diem Taxes 5.3(a) Proxy Statement Section 8.7(a5.3(b) Proceeding Shares Section 4.17 Royalties 2.1(a)(i) Statement of Merger Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) 1.3 Surviving Corporation Section 2.1 Third Milestone 1.1 Tail Period Section 2.10(g) Third Milestone Payment Amount Section 2.10(g5.9(c)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.11(b) Agreement Preamble Biogen Idec License Agreement Anglo China Preamble Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Table of Contents Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Britain Ukan Preamble Cayman Companies Law Recitals Certificates Section 2.12(f)(2) Claim Notice Section 8.3(a3.2(c) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Recitals Company Expenses Schedule Financial Advisors Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(d) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(a) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e) Company Subsidiary Section 4.1 D&O Insurance Section 6.12(b) Dissenter Rights Section 3.1(f) Dissenting Shares Section 3.1(f) Dissenting Shareholders Section 3.1(f) Effective Time Section 2.3 End Date Section 8.1(b)(i) Exchange Fund Section 3.2(a) Financing Section 5.6 Founder Vehicle Preamble HKIAC Section 9.7(c) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Independent Committee Recitals Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Lender Section 8.2(a)(ii) Damages 5.6 Loan Agreement Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) 5.6 Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Table of Contents Parent Disclosure Group Section 8.2(d) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.2 Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b4.4(b) Surviving Corporation Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)
Appears in 1 contract
Sources: Merger Agreement (China Nuokang Bio-Pharmaceutical Inc.)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: $ Section hereof in which such term is defined: 1.3(c) Adverse Recommendation Change Section 6.2(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.2(c) Arbitrator Section 4.7 Books and Records 10.8(b) Base Premium Section 2.12(f)(27.4(d) Claim Notice CICL Section 8.3(a) 2.1 Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.2(a) Company Disclosure Schedule Article IV Group Section 9.2(h) Company Expenses Schedule Intellectual Property Rights Section 2.13 4.11(a) Company Indemnified Parties Termination Fee Section 8.2(a)(ii9.2(e) Contracts Competing Proposal Section 4.8(a6.2(g) Covered Party (PartiesPersons Section 7.4(a) Dissenting Shareholders Section 8.2(a)(ii3.3(a) Damages Dissenting Shares Section 8.2(a)(i3.3(a) DGCL Dollars Section 2.1 Document Retention Period Section 2.12(f)(21.3(c) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Equity Commitment Letter Section 5.5(a) ERISA Affiliate Equity Financing Section 4.13(a5.5(a) Finally Determined Exchange Act Section 8.5(b4.5 Exchange Fund Section 3.2(a) First Milestone Financial Statements Section 2.10(e4.6(b) First Milestone Payment Amount Fuling Global, Inc. Section 2.10(e2.6 GAAP Section 4.6(b) Indemnifying Party Governmental Entity Section 8.3(a4.5 HKIAC Section 10.8(b) Instrument Indemnification Agreements Section 2.12(c7.4(a) Legal Proceeding Section 4.12 Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.2(a) Merger Sub Preamble Nasdaq Section 4.5 Non-Required Remedy Section 7.2(e) Parent Preamble Parent Disclosure Group Section 9.2(h) Parent Termination Fee Section 9.2(f) Parties Preamble Party Preamble Paying Agent Section 3.2(a) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 Proxy Statement Section 4.5 Record Date Section 6.4(a) Regulatory Filings Section 4.5 Rollover Shareholders Recitals Rules Section 10.8(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.3(a) parties Preamble Payee SEC Section 8.5 Payor 4.5 SEC Documents Section 8.5 Per Diem Taxes 4.6(a) Securities Act Section 8.7(a4.8 Share Certificates Section 3.2(b)(i) Proceeding Special Committee Recitals Superior Proposal Section 4.17 Royalties Section 2.10(h6.2(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Support Agreements Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Entity Section 2.1 Third Milestone Takeover Statute Section 2.10(g) Third Milestone Payment Amount 4.16 Transaction Litigation Section 2.10(g7.7 Transactions Recitals Uncertificated Shares Section 3.2(b)(i)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.12 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(c)(ii) Alternative Financing Section 4.7 Books 6.6(b) Alternative Financing Agreements Section 6.6(b) Anti-Corruption Laws Section 4.5(b) Articles of Merger Section 2.3 Bankruptcy and Records Equity Exception Section 2.12(f)(24.3(a) Claim Notice BVI Companies Act Preamble Certificates Section 8.3(a3.2(c)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(f)(i) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(e) D&O Insurance Section 6.12(b) Debt Commitment Letter Section 5.6(a) Debt Financing Agreement Section 6.6(a) Dissenter Rights Section 3.1(e) Dissenting Shareholders Section 3.1(e) Dissenting Shares Section 3.1(e) Effective Time Section 2.3 End Date Section 8.1(b)(i) Exchange Fund Section 3.2(b) Financing Section 5.6(a) Financing Agreements Section 6.6(b) Guarantor Preamble HKIAC Section 9.7(b) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Intervening Event Section 4.8(a6.4(e)(i) Covered Party (PartiesInvestments Section 4.2(d) Leased Real Property Section 8.2(a)(ii4.17(b) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Section 8.2(f)(i) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 PRC VIEs Section 4.21(a) Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble Rollover Securityholder Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Special Committee Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Support Agreement Preamble Super Majority Section 2.12(b) Surviving Corporation Company Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)(i)
Appears in 1 contract
Sources: Merger Agreement (China Customer Relations Centers, Inc.)
Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Acquisition Proposal Section 7.7(a) ARRA Section 4.11(g) Audited Financial Statements Section 6.13 Auditor’s Consent Section 6.13 Bankruptcy and Equity Exception Section 4.2(a) Buyer Preamble Biogen Idec License Agreement Business Software Section 4.7 Biogen Idec Supply Agreement 4.13(i) Buyer Indemnitees Section 4.7 Books and Records 12.2(a) Cap Section 2.12(f)(212.3(c)(i) Calculation Notice Section 3.2(b) Change In Control Customer Contracts Section 4.14(d) Closing Section 9.1 Closing Date Section 9.1 Closing Date Interest Rate Section 3.2(d) CMS Preamble CMS Group Charter Documents Section 4.1(b) CMS Group Release Section 7.8 COBRA Section 4.11(g) Coventry Preamble Cure Period Section 11.1(b) Deductible Section 12.3(a) Disputed Items Section 3.2(b) D&O Obligations Section 6.12 D&O Released Parties Section 12.6 Excluded Assets Section 2.2(a) FHC Recitals FHC Stock Recitals FHS Recitals FHS Closing Date Balance Sheet Section 3.2(a) FHS Closing Date Payment Section 2.4(a) FHS Estimated Working Capital Section 3.1(a) FHS Financial Statements Section 4.5(a) FHS Initial Calculation Section 3.2(a) FHS Interim Financial Statements Section 4.5(a) FHS Material Permits Section 4.17 FHS Negative Estimated Working Capital Adjustment Section 3.1(a) FHS Positive Estimated Working Capital Adjustment Section 3.1(a) FHS Restricted Business Section 7.3(a) FHS Stock Recitals FHS Working Capital Adjustment Amount Section 3.2(d) FHS Year End Financial Statements Section 4.5(a) Final FHS Working Capital Section 3.2(d) FIRPTA Affidavit Section 9.2(l) First Health Group Preamble Foreign Plans Section 4.11(h) Fundamental Representations Section 12.1(a) Governmental Damages Section 10.2(e) Governmental Investigation Section 10.2(e) HIPAA Section 4.11(g) Hired Employees Section 7.2(b)(i) HSR Filing Section 6.5(b) Indemnifiable Losses Section 12.2(b) Indemnification Notice Section 12.5(a) Indemnified Party Section 12.2(c) Infringes Section 4.13(b) Injunctions Section 10.1(b) Labor Union Section 4.12(a) Legal Actions Section 10.1(c) Loss of Profits Section 12.3(f) Material Contract Section 4.14(b) Party or Parties Preamble Policies Section 4.15 Property Taxes Section 8.2(b)(i) Provider Synergies Recitals Provider Synergies Interests Recitals Purchase Price Section 2.4(a) Re-Calculated FHS Working Capital Section 3.2(e) Re-Calculated FHS Working Capital Adjustment Amount Section 3.2(e) Registered IP Section 4.13(a) Related Persons Section 4.19 Releasing Parties Section 12.6 Restraints Section 10.1(c) Seller Indemnifiable Losses Section 12.2(b) Seller Indemnitees Section 12.2(b) Settlement Firm Section 3.2(c) Shares Recitals Tax Claim Notice Section 8.3(a) Closing Tax Return Notice Section 2.3 Closing 8.1(b)(i) Tax Settlement Firm Section 8.1(b)(i) Termination Date Section 2.3 Company Preamble Company Common Stock 11.1(e)(i) Third Party Claim Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii12.4(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Transfer Taxes Section 8.7(a8.2(a) Proceeding Unsold Securities Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)7.9
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Aggregate Outstanding Claims Section 2.9(b) Agreement Preamble Biogen Idec License Agreement Basket Amount Section 4.7 Biogen Idec Supply Agreement 8.5(a) Benefit Plan(s) Section 4.7 Books and Records 4.14(a) CERCLA Section 2.12(f)(2) 4.13 Claim Notice Section 8.3(a) Closing Section 2.3 Closing Amount Section 2.10(a) Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 2.8(a) Company Preamble Company Disclosure Schedule Article IV Company Expenses Schedule Dissenting Shares Section 2.13 2.11 Company Indemnified Parties Partner Section 8.2(a)(ii) Contracts Section 4.8(a) 4.27 Covered Party (Parties) Section 8.2(a)(ii8.2(a) Damages Section 8.2(a)(i8.2(a) DGCL Section 2.1 Document Retention Period Dispute Notice Section 2.12(f)(22.13(h) Drug Regulatory Agency Section 4.25 4.27 Effective Time Section 2.2 Employee Loans Section 4.8(a) Environmental Laws Section 4.13 Equityholder Representative Preamble ERISA Section 4.13(a4.14(a) ERISA Affiliate Section 4.13(a4.14(a) Finally Determined Escrow Account Section 8.5(b2.9(a) Escrow Agent Section 2.9(a) Escrow Agreement Section 2.9(a) Escrow Amount Section 2.9(a) Escrow Earnings Section 2.9(c) First Milestone Section 2.10(e) First Milestone MAA Subsequent Payment Amount Section 2.10(e) Indemnifying Party First NDA Subsequent Payment Amount Section 8.3(a2.10(f) Hazardous Materials Section 4.13 HSR Act Section 4.17 Instrument Section 2.12(c2.13(c) IRS Section 4.14(d) Majority Section 2.13(b) Material Contracts Section 4.8(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Net Cash Section 4.10(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Parent-Prepared Tax Return Section 8.2(a)(i6.2(a) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Preferred Stock Section 2.8(a) Proceeding Section 4.17 Royalties 4.18 Real Property Section 4.5(c) Required Company Stockholder Vote Section 4.3 Retained Escrow Amount Section 2.9(b) Rules Section 4.28 Second MAA Subsequent Payment Amount Section 2.10(g) Second NDA Subsequent Payment Amount Section 2.10(h) Second Milestone Series A Preferred Stock Section 2.10(f2.8(a) Second Milestone Payment Amount Section 2.10(fStockholder(s) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Tax Consent Section 2.10(g6.2(c) Third Milestone Payment Amount Transaction Fee Schedule Section 2.10(g)2.14
Appears in 1 contract
Sources: Merger Agreement (Pharmion Corp)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.4(a) Action Section 5.14 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Bankruptcy Exception Section 2.12(f)(25.12(b) Claim Notice Board Appointment Date Section 8.3(a2.4(a) Certificates Section 4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 COI Section 5.13(a)(vi) Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recommendation Section 2.3(a)(iv) Company Common Stock Recitals Company Disclosing Party Section 2.8 1.1(cc) Company Disclosure Schedule Article IV Documents Section 7.20(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.6(b) Contracts Company Intellectual Property Section 4.8(a5.16(b) Covered Party (PartiesCompany Material Contract Section 5.12(a) Company Plan(s) Section 8.2(a)(ii5.10(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document Retention Period 7.4(a) Company SEC Filings Section 2.12(f)(25.6(a) Drug Regulatory Agency Company Stockholder Approval Section 4.25 5.3(b) Company Stockholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.25 Continuing Directors Section 2.4(a) Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.25 End Date Section 9.1(b) ERISA Section 4.13(a5.10(a) ERISA Affiliate Section 4.13(a5.10(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone Indemnified Parties Section 2.10(e7.12(a) First Milestone Payment Amount Independent Directors Section 2.10(e2.4(b) Indemnifying Party Investments Section 8.3(a5.2(d) Instrument IRS Section 2.12(c5.10(b) JV Partner Section 1.1(o) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d)(iii) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Parent Preamble Parent Disclosure Expenses Section 9.4(c) Parent Plans Section 7.18(a) Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Purchaser Welfare Benefit Plans Section 7.18(c) Reimbursable Expenses Section 9.4(c) SCC Section 3.3 Schedule Article V Parent Indemnified Parties TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Software Section 8.5 Per Diem Taxes Section 8.7(a1.1(kk) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Support Agreement Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g2.3(a)(iii) Top-Up Option Section 2.2(a) Top-Up Option Shares Section 2.2(d) VSCA Section 2.2(a)
Appears in 1 contract
Sources: Merger Agreement (Sutron Corp)
Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms used have the meanings set forth in this Agreement and a reference to the Sections indicated: Term Section hereof in which such term is defined: 2017 Financial Statements Section 5.13(a) Acquisition Transaction Section 5.9 Agreement Preamble Biogen Idec License Agreement Agreements and Instruments Section 4.7 Biogen Idec Supply Agreement 4.12 Allocation Statement Section 4.7 Books and Records 2.7(a) Annual Financial Statements Section 2.12(f)(23.6 Antitrust Laws Section 5.4(b) Claim Notice Balance Sheet Section 8.3(a3.6 Balance Sheet Date Section 3.6 Basket Section 8.5(a) Cash Consideration Amount Section 2.2(a) Closing Section 7.4 Closing Cash Consideration Section 2.3 Closing Date Section 7.4 Closing Net Working Capital Section 2.4(a) Closing Statement Section 2.4(a) Company Released Parties Section 5.10(a) Cumulative Revenue Make Up Amount Section 2.5(a) Dispute Notice Section 2.4(b) Disputed Amount Section 2.6(b) Earnout Recipients Section 2.5(d) Earnout Statement Section 2.5 Employee Benefit Plans Section 3.14(a) Equity Interests Recitals Estimated Closing Statement Section 2.3 Company Estimated Net Working Capital Section 2.3 FCPA Section 3.17(c) Financial Statements Section 3.6 Fraud Claims Section 8.1(b) ▇. ▇▇▇▇▇▇ Guaranties Section 5.14 HSR Act Section 3.5(b) Indemnification Claim Section 8.4(a) Indemnity Cap Section 8.5(d) Insurance Policies Section 3.21 Interim Financial Statements Section 3.6 Leased Real Property Section 3.10(a) Losses Section 8.2(a) Material Contracts Section 3.13(a) Material Customers Section 3.24(a) Material Vendors Section 3.24(a) Non-Disclosure Agreement Section 5.6(a) NYSE Section 4.13 Objection Notice Section 2.5(c) Party and Parties Preamble Company Payoff Letters Section 7.1(i) Personal Property Leases Section 3.11 Purchaser Preamble Purchaser Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.2(a) Purchaser Documents Section 2.13 Company 4.2 Purchaser Financial Statements Section 4.10 Purchaser Indemnified Parties Section 8.2(a)(ii8.2(a) Contracts Purchaser Plans Section 4.8(a6.1(b) Covered Party (PartiesPurchaser Preferred Stock Section 4.9(a) Purchaser SEC Documents Section 8.2(a)(ii4.11(a) Damages R&W Policy Premium Section 8.2(a)(i8.10 Real Property Leases Section 3.10(a) DGCL 93 Required Quarter Financial Statements Section 2.1 Document Retention Period 5.13(a) Rights-of-Way Section 2.12(f)(23.10(a) Drug Regulatory Agency SEC Section 4.25 Effective Time 4.10 Seller Documents Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 3.2 Seller Indemnified Parties Section 8.2(a)(i8.3 Sellers Representative Section 9.1(a) parties Sellers Preamble Payee Specified Creditors Section 8.5 Payor 2.3(b) Specified Indebtedness Section 8.5 Per Diem Taxes 2.3(b) Specified Indebtedness Statement Section 8.7(a2.3(b) Proceeding Tax Matter Section 4.17 Royalties 9.2(d) Termination Date Section 2.10(h7.5(a) Second Milestone Transaction Consideration Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)2.2
Appears in 1 contract
Sources: Equity Interest Purchase Agreement (Tetra Technologies Inc)
Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Act Section 2.1(b) Affected Employees Section 6.7(a) Agreement Preamble Biogen Idec License Agreement Date Preamble Benefit Plans Section 4.7 Biogen Idec Supply Agreement 3.16(a) Burdensome Action Section 4.7 Books and Records Section 2.12(f)(26.4(c) Claim Calculation Notice Section 8.3(a2.5(b) Closing Section 2.3 2.3(a) Closing Date Section 2.3 2.3(a) Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Preamble to Article IV 3 Company Expenses Schedule Sale Transaction Section 2.13 6.3(a) Company Indemnified Trade Secrets Section 3.12(c) Competing Business Section 6.15(a) Confidential Information Section 6.2(e) Continuation Period Section 6.7(a) Contracting Parties Section 8.2(a)(ii11.10 Contribution Recitals Conversion Recitals Credit Agreement Section 2.3(c)(iv) Contracts Debt Financing Section 4.8(a) Covered Party (Parties) 5.6 Debt Financing Commitment Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention 5.6 Dispute Period Section 2.12(f)(210.5(b) Drug Regulatory Agency DOJ Section 4.25 Effective Time 6.4(b) Enforceability Exceptions Section 2.2 3.3 ERISA Section 4.13(a3.16(a) ERISA Affiliate Estimated Cash Section 4.13(a2.3(a)(iii) Finally Determined Estimated Closing Statement Section 8.5(b2.3(a) First Milestone Estimated Indebtedness Section 2.10(e2.3(a)(ii) First Milestone Payment Amount Estimated Non-Cash Working Capital Section 2.10(e2.3(a)(i) Estimated Transaction Expenses Section 2.3(a)(iv) Final Election Allocation Section 8.3 FTC Section 6.4(b) Holdco Preamble Indemnified Party Section 10.5(a) Indemnifying Party Section 8.3(a10.5(a) Instrument Initial Calculations Section 2.12(c2.5(a) Merger Interests Recitals IT Systems Section 2.1 Merger Certificate 3.12(f) Leased Real Property Section 2.2 Merger Sub Preamble 3.22(b) Licensed Company Intellectual Property Section 3.12(b) Material Breach Section 9.2 Material Contracts Section 3.14(a) Non-Disclosure Agreement Section 6.2(d) Nonparty Affiliates Section 11.10 Notice Section 10.5(a) OFAC Section 3.9(b) Outside Date Section 9.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i10.2 Parties Preamble Party Preamble Personal Information Section 3.25 Pre-Closing Period Section 8.4(a) parties Privacy Laws Section 3.25 Proposed Election Allocation Section 8.3 Purchaser Preamble Payee Purchaser Related Parties Section 8.5 Payor 9.3(b) Purchaser Related Party Section 8.5 Per Diem 9.3(b) Real Property Leases Section 3.22(b) Registered Company Intellectual Property Section 3.12(a) Released Parties Section 10.9 Releasing Parties Section 10.9 Reorganization Recitals Restricted Commitment Amendments Section 6.13(a) Restricted Period Section 6.15(a) Reverse Termination Fee Section 9.3(a) Seller Preamble Seller Indemnified Parties Section 10.3 Seller Indemnifying Parties Section 10.2 Seller Indemnifying Party Section 10.2 Seller Parties Preamble Settlement Accountants Section 2.5(c) Straddle Period Section 8.4(a) -19- Telecommunications Providers Section 6.15(a) Third-Party Claim Section 10.5(a) Transfer Taxes Section 8.7(a) Proceeding 8.6 Transferred Employees Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.3(e)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Action Section 4.13 Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Introduction Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(b)(iii) Alternative Financing Section 4.7 Books and Records 6.6(b) Alternative Financing Commitment Section 2.12(f)(26.6(b) Claim Antitrust Laws Section 4.4(b) Capped Damages Section 8.2(a)(ii) Certificate of Merger Section 2.3 Certificates Section 3.2(b), Section 3.2(b) CFIUS Section 4.4(b) Change of Recommendation Notice Section 8.3(a6.4(e)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 COBRA Section 4.10(i) Company Preamble Introduction Company Common Adverse Recommendation Change Section 6.4(d)(i) Company Financial Advisor Section 4.21 Company Financial Statements Section 4.6(b) Company Group Section 8.2(b)(v) Company Insurance Policies Section 4.17 Company Material Contract Section 4.12(a) Company Preferred Stock Section 2.8 4.2(a) Company Disclosure Schedule Article IV Recommendation Section 4.3(b) Company Expenses Schedule Representatives Section 2.13 6.3(a) Company Indemnified Parties SEC Filings Section 8.2(a)(ii4.6(a) Contracts Company Stock Rights Section 4.8(a4.2(c) Covered Party (PartiesCompany Stockholders Meeting Section 6.2(d) Company Subsidiary Section 8.2(a)(ii4.1(a) Damages Condemnation Actions Section 8.2(a)(i4.18(d) Cut-Off Date Section 6.4(b)(vi) D&O Insurance Section 6.12(b) Debt Commitment Letters Section 5.6(a) Debt Financing Section 5.6(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.3 Effective Time Section 2.2 ERISA 2.3 End Date Section 4.13(a8.1(b)(i) ERISA Affiliate Enforcement Exceptions Section 4.13(a4.3(a) Finally Determined Equity Commitment Letter Section 8.5(b5.6(a) First Milestone Equity Financing Section 2.10(e5.6(a) First Milestone Payment Amount Exchange Fund Section 2.10(e3.2(a) Indemnifying Party Existing Debt Section 8.3(a4.2(h) Instrument Exon-▇▇▇▇▇▇ Section 2.12(c4.4(b) FCPA Section 4.27 Financing Section 5.6(a) Financing Commitments Section 5.6(a) Guarantee Recitals Guarantor Recitals Leased Real Property Section 4.18(a) Liability Section 4.7 Merger Recitals Merger Consideration Section 3.1(a) Merger Sub Introduction NDA Consent Section 2.1 Merger Certificate 6.5(e) New Plans Section 2.2 Merger Sub Preamble 6.10(c) NRC Consents Section 4.4(b) Option Cash Payment Section 3.5(b) Original Date Section 6.2(e) Owned Real Property Section 4.18(a) Parent Preamble Introduction Parent Disclosure Schedule Article V Group Section 8.2(c)(iii) Parent Indemnified Representatives Section 6.3(a) Parties Introduction Party Introduction Paying Agent Section 8.2(a)(i3.2(a) parties Preamble Payee Performance-Based Company Phantom Share Award Section 8.5 Payor 3.5(d) Present Fair Salable Value Section 8.5 Per Diem Taxes 5.11 Proxy Statement Section 8.7(a4.20 Real Property Section 4.18(a) Proceeding Real Property Leases Section 4.17 Royalties 4.18(a) Required Financial Information Section 2.10(h6.7(a) Second Milestone Restricted Stock Payment Section 2.10(f3.5(c) Second Milestone Payment Amount Solicitation Period End Date Section 2.10(f6.4(a) Solvent Section 5.11 Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b) 4.23 Surviving Corporation Section 2.1 Third Milestone Takeover Statute Section 2.10(g) Third Milestone Payment Amount 4.19 Transaction Litigation Section 2.10(g)6.8
Appears in 1 contract
Terms Defined Elsewhere. The Solely for convenience, the following is a list of additional terms used that are defined in the section of this Agreement and a reference to the Section hereof in which set forth after each such term is definedbelow: Accounting Firm Section 3.2 Accounts Receivable Section 2.1(j) Agreement Preamble Biogen Idec License Agreement Allocation Schedule Section 4.7 Biogen Idec Supply Agreement 3.2 Alternate Debt Financing Section 4.7 7.18(c) Alternative Financing Commitment Section 7.18(c) Assumed Liabilities Section 2.3 Balance Sheet Date Section 5.6 ▇▇▇▇ of Sale Section 4.2(a) Books and Records Section 2.12(f)(22.1(e) Business Related Software Section 5.14(b) Cash Purchase Price Section 3.1 Claim Notice Section 8.3(a10.4(a) Closing Section 2.3 4.1 Closing Date Section 2.3 4.1 Code Section 3.2 Company Cash Section 2.1(q) Comprint Preamble Company Common Stock Confidentiality Agreement Section 2.8 Company 7.4 Consents Section 5.5 Contract Section 2.1(g) Controversy Section 11.10 Disclosure Schedule Letter Article IV Company Expenses Schedule V Domain Name Assignment Section 2.13 Company Indemnified Parties Section 8.2(a)(ii4.2(c) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Exchange Act Article V Excluded Assets Section 2.2 ERISA Financial Statements Section 4.13(a5.6 Financing Section 6.4 Financing Commitment Section 6.4 Flex Plan Section 7.16(f) ERISA Affiliate Form 8594 Section 4.13(a3.2 Grant Deed Section 4.2(b) Finally Determined Guarantor Preamble ▇▇▇▇▇-▇▇▇▇▇ ▇▇▇▇ and Logo Section 8.5(b2.2(f) First Milestone HH Shoppers Preamble Indemnified Party Section 2.10(e) First Milestone Payment Amount Section 2.10(e10.4(a) Indemnifying Party Section 8.3(a10.4(a) Instrument of Assignment and ▇▇▇▇ of Sale Section 2.12(c4.2(a) Merger Inventory Section 2.1 Merger Certificate 2.1(i) Lease Assignment Section 2.2 Merger Sub Preamble 4.2(e) Leased Real Property Section 2.1(a)(ii) Licensed Software Section 5.14(b) Licenses and Permits Section 2.1(h) Machinery Section 2.1(c) Material Agreement Section 5.9(a) Natural Hazard Areas Section 11.20 Notice Section 11.10 Notice Period Section 10.4(c) Owned Real Property Section 2.1(a)(i) Parent Preamble Parent Disclosure Schedule Article V Benefit Plans Section 5.12 Parent Deductible Section 10.2(b)(i) Parent Indemnified Parties Section 8.2(a)(i10.3(a) parties Personal Property Leases Section 2.1(b) Party Preamble Payee Proprietary Software Section 8.5 Payor 5.14(b) Purchase Price Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation 3.1 Purchased Assets Section 2.1 Third Milestone Purchasers Preamble Purchasers Deductible Section 2.10(g10.3(b)(i) Third Milestone Payment Amount Purchasers Indemnified Parties Section 2.10(g10.2(a) Purchasers Plan Section 7.16(c) Purchasers Savings Plan Section 7.16(d) RE Purchaser Preamble Response Section 11.10 Retained Liabilities Section 2.4 Reverse Termination Fee Section 9.2 SEC Article V Sellers Preamble Software Section 5.14(b) Tax Refunds Section 2.2(b) Trademark Assignment Section 4.2(c) Transfer Tax Returns Section 7.8(a) Transferred Employees Section 7.16(a) Transferred Intellectual Property Section 2.1(d) Transition Services Agreement Section 4.2(d)
Appears in 1 contract
Terms Defined Elsewhere. The For the purposes of this Agreement, the following is a list terms have the meanings specified in the indicated Sections of additional terms used in this Agreement and a reference to the Agreement: Additional Individual Parties Preamble Additional Individual Party HoldCos Preamble Additional Number Section hereof in which such term is defined: 3.2(b) Agreement Preamble Biogen Idec License Agreement Board Section 4.7 Biogen Idec Supply Agreement 1.2(a) Business Opportunity Section 4.7 Books and Records 11.7 CEO Section 2.12(f)(21.3 CFC Section 10.4 Chairman Section 1.2(c) Claim Company Preamble Compensation Committee Section 1.2(e) Confidential Information Section 8.1 Covered Transaction Section 3.5 Co-Sale Notice Section 8.3(a6.1 Co-Sale Pro Rata Portion Section 6.1(a) Closing Co-Sale Right Period Section 2.3 Closing 6.1 Director Section 1.2(a) Disclosing Party Section 8.4 Disposal Event Section 11.1(c)(i) Exercising ROFR Holder Section 5.2(b) First Participation Notice Section 3.2(a) First Refusal Expiration Notice Section 5.2(c) First Refusal Period Section 5.2(a) Founders Preamble Founder HoldCos Preamble HKIAC Section 12.12(b) HKIAC Rules Section 12.12(b) Information Rights Holder Section 1.1(a) Initiating Holders Section 2.2(b) Inspection Rights Section 1.1(c) Investors Preamble IPO Section 2.11(c) IPO Event Section 11.1(c)(i) Key Group Company Preamble Loan Outside Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure 11.1(c)(i) MGJ OpCo Schedule Article IV Company Expenses A-1 MLS Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention A-1 MLS OpCo Schedule A-1 Non-Competition Period Section 2.12(f)(211.4 Offered Shares Section 5.1 Onshore Equity Transfer Section 11.12 Onshore Personnel Replacement Section 11.12 Ordinary Director/Ordinary Directors Section 1.2(c) Drug Regulatory Agency Overallotment New Securities Section 4.25 Effective Time 3.2(b) Oversubscribing Right Participants Section 2.2 ERISA 3.2(b) Participation Rights Holder Section 4.13(a3.1 Party/Parties Preamble Permitted Transferee Section 4.4 PFIC Section 10.3 PFIC Shareholder Section 10.3 Preferred Director/Preferred Directors Section 1.2(b) ERISA Affiliate Prior Shareholders Agreement Recital (A) Re-allotment Period Section 4.13(a5.2(b) Finally Determined Re-allotment Share Number Section 8.5(b5.2(b) First Milestone Request Notice Section 2.10(e2.2(a) First Milestone Payment Amount Right of Participation Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)3.1
Appears in 1 contract
Sources: Shareholder Agreement (Meili Inc.)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: "Agreement" Preamble "Certificate of Merger" Section hereof in which such term is defined: Agreement 1.2 "Certificates" Section 2.2.2 "Company" Preamble Biogen Idec License Agreement "Company Benefit Plan" Section 4.7 Biogen Idec Supply Agreement 3.12.1 "Company Board" Recitals "Company By-laws" Section 4.7 Books and Records 3.2 "Company Certificate" Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble 3.2 "Company Common Stock Stock" Section 2.8 2.1.1 "Company Disclosure Schedule Schedule" Article IV 3 "Company Expenses Schedule Employees" Section 2.13 5.10 "Company Indemnified Parties Financial Advisor" Section 8.2(a)(ii) Contracts 3.17 "Company Leased Property" Section 4.8(a) Covered Party (Parties) 3.8.1 "Company Material Contract" Section 8.2(a)(ii) Damages 3.11 "Company Options" Section 8.2(a)(i) DGCL 2.5 "Company Owned Property" Section 2.1 Document Retention Period 3.8.1 "Company Permits" Section 2.12(f)(2) Drug Regulatory Agency 3.19.1 "Company Real Property" Section 4.25 3.8.1 "Company Representatives" Section 5.5 "Company SEC Filings" Section 3.5.1 "Company Stockholders' Meeting" Section 5.4 "Company Subsidiaries" Section 3.1 "D&O Insurance" Section 5.11.2 "Dissenting Stockholders" Section 2.1.1 "DGCL" Recitals 38 "Effective Time Time" Section 2.2 1.2 "ERISA" Section 3.12.1 "ERISA Affiliate" Section 4.13(a) ERISA Affiliate 3.12.1 "▇▇▇▇▇▇ Street Agreement" Section 4.13(a) Finally Determined 3.8.11 "IRS" Section 8.5(b) First Milestone 3.7.5 "Lease Documents" Section 2.10(e) First Milestone Payment Amount 3.8.3 "Material Intellectual Property" Section 2.10(e) Indemnifying Party 3.10 "Merger" Recitals "Merger Consideration" Section 8.3(a) Instrument 2.1.1 "Merger Sub" Preamble "Multiemployer Plan" Section 2.12(c) Merger 3.12.3 "Option Payment" Section 2.1 Merger Certificate 2.5 "Outside Date" Section 2.2 Merger Sub 7.1.2 "Parent" Preamble "Parent Preamble Benefit Plan" Section 5.10 "Parent Disclosure Schedule" Article 4 "Parent Representatives Section 5.5 "Parent Subsidiaries" Recitals "Paying Agent" Section 2.2.1 "Payment Fund" Section 2.2.1 "PBGC" Section 3.12.4 "Permitted Exceptions" Section 3.8.2 "Proxy Statement" Section 5.3.1 "Qualifying Acquisition Proposal" Section 5.6.1 "Regulatory Conditions" Section 7.1.2 "Requisite Stockholder Approval" Section 3.18 "Schedule Article V 13E-3" Section 5.3.1 "Separation Agreements" Recitals "Special Committee" Recitals "Surviving Corporation" Section 1.1 "Surveys" Section 3.8.2 "Taxes" Section 3.7.13 "Tax Return" Section 3.7.13 "Terminating Company Breach" Section 7.1.5 39 "Terminating Parent Indemnified Parties Breach" Section 8.2(a)(i) parties Preamble Payee 7.1.6 "Title Policies" Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)3.8.2 "Voting Agreements" Recitals
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Acquired Assets Acquired Assets Permits Acquired Assets Regulatory Filings Aggregate Threshold Agreed Amount Agreement and a reference to the Antitrust Approvals Assigned Contracts Assigned IP Contracts Assumed Liabilities Assumption Agreements Bill of Sale Burdensome Term or Condition Section hereof in which such term is defined: Agreement 1.01(a) Section 2.12(a) Section 2.12(a) Section 6.05(b)(ii) Section 6.04 (b) Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement 4 .03(b) Section 4.7 Books and Records 1.01(a)(iv) Section 2.12(f)(21.01(a)(iv) Section 1.01(d) Section 1.01(d) Section 1.03(b)(iii) Section 4 .03(f) 49 Ame ric as 9 2 4 2 5 1 0 0 Buyer Preamble Buyer FDA Letter Section 5.03(e) Buyer Group Section 1.01(a) Buyer Indemnified Parties Section 6.02 Buyer Orphan Designation Letter Section 5.03(e) Cap Section 6.05(b)(i) CF Enterprise Recitals Claim Notice Section 8.3(a6.04 (b) Claimed Amount Section 6.04 (b) Closing Section 2.3 1.03(a) Closing Date Section 2.3 Company 1.03(a) Confidentiality Agreement Section 4 .02 Contingent Payment Section 1.02(b) CTAs Section 2.10(a)(viii) DOJ Section 4 .03(a) Electronic Delivery Section 10.07 Excluded Assets Section 1.01(b) Excluded Liabilities Section 1.01(e) FDA Section 2.12(a) FDCA Section 2.12(a) FTC Section 4 .03(a) Fundamental Representations Section 6.01(a) Guarantor Preamble Company Common Stock HSR Act Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.05(c) Indemnified Party Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party 6.04 (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(ea) Indemnifying Party Section 8.3(a6.04 (a) Instrument IP Assignment Agreements Section 2.12(c1.03(b)(iv) Merger Material Contract Section 2.1 Merger Certificate 2.10(a) MTAs Section 2.2 Merger Sub 2.10(a)(viii) NDAs Section 2.10(a)(viii) Non‑Compete Period Section 9.05(a) Outside Date Section 7.01(f)(ii) Parties Preamble Parent Party Preamble Parent PHSA Section 2.12(a) Pre‑Closing Period Section 4 .01(a) Research and Testing Agreement Recitals Registered Business IP Section 2.09(a) Regulatory Authority Section 2.12(a) Regulatory Filings Section 4 .03(a) Related Agreements Section 2.03 Restricted Names Section 9.02 Safety Notice Section 2.12(d) Ame ric as 9 2 4 2 5 1 0 0 Seller Preamble Seller Board Section 2.03 Seller Board Approval Section 2.20 Seller Change of Recommendation Section 4 .07(c) Seller Disclosure Schedule Letter Article V Parent II Seller FDA Letter Section 5.02(f) Seller Indemnified Parties Section 8.2(a)(i6.03 Seller Orphan Designation Letter Section 5.02(f) parties Preamble Payee Supplement Section 8.5 Payor 4 .04 Termination Fee Section 8.5 Per Diem 7.02(b) Third Party Claim Section 6.04 (a) Third Party IP Section 2.09(f) Transfer Taxes Section 8.7(a8.01(a) Proceeding Transferred IP Section 4.17 Royalties 1.01(a)(ii) Transferred IP Documentation Section 2.10(h1.01(a)(iii) Second Milestone Transferred Permits Section 2.10(f1.01(a)(vi) Second Milestone Payment Amount Transition Services Agreement Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.03(b)(vii)
Appears in 1 contract
Sources: Asset Purchase Agreement
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.4(e) Adverse Recommendation Section 6.2 Agreement Preamble Biogen Idec License Agreement Alternative Company Acquisition Section 4.7 Biogen Idec Supply Agreement 6.3(g)(ii) Alternative Financing Section 4.7 Books and Records 6.11(c) Alternative Vistas Acquisition Section 2.12(f)(26.3(f)(i) Claim Notice Anghami Merger Sub Preamble Anghami Merger Surviving Company Section 8.3(a2.1(b) Cayman Plan of Merger for the Anghami Merger Section 2.1(b) Cayman Plan of Merger for the Vistas Merger Section 2.1(a) CFO Section 2.2(b)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Closing Form 8-K Section 6.4(c) Closing Press Release Section 6.4(c) Communication Policy Section 6.3(h) Company Preamble Company Common Stock Acquisition Proposal Section 2.8 6.3(g)(ii) Company Disclosure Schedule Article IV Class A Shares Section 3.3 Company Expenses Schedule Class C Shares Section 2.13 3.3 Company Closing Statement Section 2.4(a)(i) Company Employee Benefit Plan Section 3.15(a) Company Permits Section 3.17(b) Company Seed Preferred Shares Section 3.3 Company Series A Preferred Shares Section 3.3 Company Series A+ Preferred Shares Section 3.3 Company Shareholders Section 3.3 D&O Claim Section 6.9(a) D&O Entity Section 6.9(a) D&O Indemnification Obligation Section 6.9(d) D&O Indemnified Parties Person Section 8.2(a)(ii6.9(a) Contracts Data Room Section 4.8(a) Covered Party (Parties) 10.5 Dispute Section 8.2(a)(ii) Damages 10.9 Dispute Notice Section 8.2(a)(i) DGCL Section 2.1 Document Retention 10.9 Dispute Resolution Period Section 2.12(f)(210.9 Equity Financing Section 6.11 Financial Statements Section 3.4(a) Drug Regulatory Agency ICDR Section 4.25 Effective Time 10.9 ICDR Rules Section 2.2 ERISA 10.9 Latest Balance Sheet Section 4.13(a3.4(a) ERISA Material Contract Section 3.10(a) Non-Party Affiliate Section 4.13(a10.7 Other Indemnitors Section 6.9(d) Finally Determined Outside Date Section 8.5(b9.1(c) First Milestone Party, Parties Preamble Post-Closing Pubco Board Section 2.10(e2.1(d) First Milestone Payment Amount Pre-Closing Period Section 2.10(e6.3 Registration Statement Section 6.1(a) Indemnifying Party Pubco Preamble Pubco Assumed Option Section 8.3(a2.3(b)(ii) Instrument Public Stockholders Section 2.12(c10.11 Relevant Period Section 3.22 Restrictive Covenant Agreement Recitals Signing Form 8-K Section 6.4(b) Signing Press Release Section 6.4(b) Sponsor Letter Agreement Recitals Registration Rights Agreement Section 8.2(d)(iv) Tail Policy Section 6.9(c) Transactions Recitals Vistas Preamble Vistas Acquisition Proposal Section 6.3(f)(i) Vistas Benefit Plans Section 5.14 Vistas Material Contract Section 5.8 Vistas Merger Section 2.1 Merger Certificate Section 2.2 Recitals Vistas Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Vistas Merger Surviving Company Section 8.2(a)(i2.1(a) parties Preamble Payee Vistas Preferred Shares Section 8.5 Payor 5.2 Vistas Public Securities Section 8.5 Per Diem Taxes 5.15 Vistas Record Date Section 8.7(a6.1(a) Proceeding Vistas SEC Documents Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.5
Appears in 1 contract
Sources: Business Combination Agreement (Vistas Media Acquisition Co Inc.)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Recommendation Change Section hereof in which such term is defined: 6.2(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.2(c) Arbitrator Section 4.7 Books and Records 10.8(b) Base Premium Section 2.12(f)(27.4(d) Claim Notice CICA Section 8.3(a) 2.1 Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Benefit Plans Section 2.8 4.12(a) Company Disclosure Schedule Article IV Board Recitals Company Expenses Schedule Board Recommendation Recitals Company Equity Interests Section 2.13 4.2(a) Company Indemnified Parties Group Section 8.2(a)(ii9.2(h) Contracts Company Material Properties Section 4.8(a4.19(b) Company Permits Section 4.18(b) Company Termination Fee Section 9.2(e) Competing Proposal Section 6.2(g) Contract Section 4.15(a) Covered Party (PartiesPersons Section 7.4(a) Data Protection Laws Section 8.2(a)(ii4.17(j) Damages Dissenting Shareholders Section 8.2(a)(i3.5(a) DGCL Dissenting Shares Section 2.1 Document Retention Period 3.5(a) Dollars Section 2.12(f)(21.3(c) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 EP toxicity Section 1.1 Equity Commitment Letters Section 5.5(a) ERISA Affiliate Equity Financing Section 4.13(a5.5(a) Finally Determined Exchange Act Section 8.5(b4.5 Exchange Fund Section 3.4(a) First Milestone FCPA Section 2.10(e4.18(c) First Milestone Payment Amount Financial Statements Section 2.10(e4.6(b) Indemnifying Party GAAP Section 8.3(a4.6(b) Instrument Governmental Entity Section 2.12(c4.5 HKIAC Section 10.8(b) Indemnification Agreements Section 7.4(a) Intervening Event Section 6.2(d) IP Rights Agreements Section 4.17(d) Legal Proceeding Section 4.11 Limited Guarantee Recitals Material Contract Section 4.15(b) Merger Recitals Merger Consideration Section 3.4(a) Merger Sub Recitals NASDAQ Section 4.5 Open Source Materials Section 4.17(j) Parent Parent Parent Group Section 9.2(h) Parent Group Contracts Section 5.8 Parent Termination Fee Section 9.2(f) Party Preamble Paying Agent Section 3.4(a) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 PRC Subsidiaries Section 4.10(a) Protected Information Section 4.17(i) Proxy Statement Section 4.5 Record Date Section 6.4(a) Registrar of Companies Section 2.3 Risk Factors Article IV Rules Section 10.8(b) Sanctions Section 4.18(c) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule 13E-3 Section 6.3(a) SEC Section 4.5 SEC Documents Section 4.6(a) Securities Act Section 4.6(a) Share Certificates Section 3.4(b)(i) Special Committee Recitals Superior Proposal Section 6.2(h) Support Agreement Recitals Surviving Entity Section 2.1 Merger Certificate Takeover Statute Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties 4.25 Transaction Litigation Section 8.2(a)(i7.7 Transactions Recitals Uncertificated Shares Section 3.4(b)(i) parties Preamble Payee VIE Contracts Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.10(c)
Appears in 1 contract
Sources: Merger Agreement (GLORY STAR NEW MEDIA GROUP HOLDINGS LTD)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acquired Assets Section hereof in which such term is defined: 1.01(a) Acquired Assets Permits Section 2.12(a) Acquired Assets Regulatory Filings Section 2.12(a) Aggregate Threshold Section 6.05(b)(ii) Agreed Amount Section 6.04(b) Agreement Preamble Biogen Idec License Agreement Antitrust Approvals Section 4.7 Biogen Idec Supply Agreement 4.03(b) Assigned Contracts Section 4.7 Books and Records 1.01(a)(iv) Assigned IP Contracts Section 2.12(f)(21.01(a)(iv) Assumed Liabilities Section 1.01(d) Assumption Agreements Section 1.01(d) ▇▇▇▇ of Sale Section 1.03(b)(iii) Burdensome Term or Condition Section 4.03(f) Americas 92425100 Buyer Preamble Buyer FDA Letter Section 5.03(e) Buyer Group Section 1.01(a) Buyer Indemnified Parties Section 6.02 Buyer Orphan Designation Letter Section 5.03(e) Cap Section 6.05(b)(i) CF Enterprise Recitals Claim Notice Section 8.3(a6.04(b) Claimed Amount Section 6.04(b) Closing Section 2.3 1.03(a) Closing Date Section 2.3 Company 1.03(a) Confidentiality Agreement Section 4.02 Contingent Payment Section 1.02(b) CTAs Section 2.10(a)(viii) DOJ Section 4.03(a) Electronic Delivery Section 10.07 Excluded Assets Section 1.01(b) Excluded Liabilities Section 1.01(e) FDA Section 2.12(a) FDCA Section 2.12(a) FTC Section 4.03(a) Fundamental Representations Section 6.01(a) Guarantor Preamble Company Common Stock HSR Act Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.05(c) Indemnified Party Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e6.04(a) Indemnifying Party Section 8.3(a6.04(a) Instrument IP Assignment Agreements Section 2.12(c1.03(b)(iv) Merger Material Contract Section 2.1 Merger Certificate 2.10(a) MTAs Section 2.2 Merger Sub 2.10(a)(viii) NDAs Section 2.10(a)(viii) Non‑Compete Period Section 9.05(a) Outside Date Section 7.01(f)(ii) Parties Preamble Parent Party Preamble Parent PHSA Section 2.12(a) Pre‑Closing Period Section 4.01(a) Research and Testing Agreement Recitals Registered Business IP Section 2.09(a) Regulatory Authority Section 2.12(a) Regulatory Filings Section 4.03(a) Related Agreements Section 2.03 Restricted Names Section 9.02 Safety Notice Section 2.12(d) Americas 92425100 Seller Preamble Seller Board Section 2.03 Seller Board Approval Section 2.20 Seller Change of Recommendation Section 4.07(c) Seller Disclosure Schedule Letter Article V Parent II Seller FDA Letter Section 5.02(f) Seller Indemnified Parties Section 8.2(a)(i6.03 Seller Orphan Designation Letter Section 5.02(f) parties Preamble Payee Supplement Section 8.5 Payor 4.04 Termination Fee Section 8.5 Per Diem 7.02(b) Third Party Claim Section 6.04(a) Third Party IP Section 2.09(f) Transfer Taxes Section 8.7(a8.01(a) Proceeding Transferred IP Section 4.17 Royalties 1.01(a)(ii) Transferred IP Documentation Section 2.10(h1.01(a)(iii) Second Milestone Transferred Permits Section 2.10(f1.01(a)(vi) Second Milestone Payment Amount Transition Services Agreement Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.03(b)(vii)
Appears in 1 contract
Sources: Asset Purchase Agreement (Vertex Pharmaceuticals Inc / Ma)
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: 2023 45X Credit Section 2.9(a) 2024 45X Credit Section 2.9(a) 2025 45X Credit Section 2.9(a) 401(k) Plan Section 7.3(b) Accounting Firm Section 2.4(b) Active Job Section 3.5(i) Affiliate Arrangements Section 3.22 Agreement Preamble Biogen Idec License Allocation Schedule Section 7.2(e) Antitrust Laws Section 7.12(c) Benefits Transition Period Section 7.3(a) Benefits Transition Services Section 7.3(a) Binder Agreement Section 4.7 Biogen Idec Supply Agreement 7.11 Buyer Preamble CBA Section 4.7 Books and Records 3.7(d) Claims Section 2.12(f)(2) Claim Notice Section 8.3(a) 7.8 Closing Section 2.3 2.7(a) Closing Date Section 2.3 2.7(a) Closing Item Section 2.4(a) Closing Payment Section 2.7(d)(vi) Closing Statement Section 2.4(a) Company Preamble Company Common Employee Benefit Plan Section 3.15(a) Company Interests Recitals Company Licenses Section 3.17(b) Company Proprietary Rights Section 3.12(a) Company Transaction Section 7.1(d) Confidential Information Section 7.13(a) Customer Assets Section 3.28 Deferred Consideration Section 2.6(a) Deferred Consideration Anniversary Section 2.6(a) Deferred Consideration Installment Section 2.6(a) Deferred Consideration Shares Section 2.6(a) Dispute Notice Section 2.4(b) Earnout Stock Section 2.8 Company Disclosure Schedule Article IV Company 2.5 Effective Date Preamble Employed Guarantor Section 2.6(c) End Date Section 8.1(d) Estimated Cash Section 2.3(a)(i) Estimated Closing Statement Section 2.3(a) Estimated Indebtedness Section 2.3(a)(i) Estimated Transaction Expenses Schedule Section 2.13 Company Indemnified Parties 2.3(a)(i) Estimated Working Capital Section 8.2(a)(ii2.3(a)(i) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Excess Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.4(d)
Appears in 1 contract
Sources: Equity Purchase Agreement (Array Technologies, Inc.)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 280G Stockholder Approval Section hereof in which such term is defined: 5.6(b) 401(k) Plan Section 1.4(b)(i) Adjustment Resolution Period Section 1.15(b) Adjustment Review Period Section 1.15(b) Agreement Preamble Biogen Idec License Agreement Date Preamble Allocation Schedule Section 4.7 Biogen Idec Supply Agreement 4.3(a) Anti-Corruption Laws Section 4.7 2.24 Balance Sheet Date Section 2.7(b) Behavioral Data Section 2.12(a)(i) Board Recitals Books and Records Section 2.12(f)(22.17(b) Cancelled Shares Section 1.7(e) Cash Portion Section 4.2(f) CCPA Section 2.12(a)(xiv) Certificate of Incorporation Section 2.1(d) Certificate of Merger Section 1.2(a) Certificates of Merger Section 1.2(b) Charter Documents Section 2.1(d) Closing Section 1.4(a) Closing Date Section 1.4(a) Company Preamble Company Authorizations Section 2.15 Company Board Resolutions Section 2.4(a) Company Data Section 2.12(a)(ii) Company Indemnitees Section 4.5(a) Company IP Section 2.12(a)(iii) Company Owned IP Section 2.12(a)(iv) Company Prepared Returns Section 4.2(a)(i) Company Privacy Policy Section 2.12(a)(v) Company Products Section 2.12(a)(vi) Company Products Data Section 2.12(a)(vii) Company Registered IP Section 2.12(b) Company Software Section 2.12(a)(viii) Company Source Code Section 2.12(a)(ix) Company Stockholder Approval Recitals Company Voting Debt Section 2.2(f) Confidentiality Agreement Section 5.7 Contaminant Section 2.12(a)(x) Continuing Claim Section 7.4(f) Converted Option Section 1.7(b)(ii) Converted Option Exercise Price Section 1.7(b)(ii) Current Balance Sheet Section 2.7(b) D&O Indemnifiable Matters Section 4.5(a) D&O Tail Policy Section 4.5(b) Deductible Amount Section 7.3(a) Delaware LLC Act Section 1.1(b) Determination Date Section 1.15(c) DGCL Section 1.1(a) Director and Officer Resignation Letters Section 1.4(b)(iv) Disclosure Schedule Article II Dissenting Shares Section 1.11(a) Effective Time Section 1.2(a) Eligible Continuing Employee Section 5.19 Embargoed Countries Section 2.23 End Date Section 8.1(b) Engagement Letter Section 7.6(b) ePrivacy Directive Section 2.12(a)(xiv) Escrow Agreement Section 1.4(b)(xi) Escrow Fund Section 1.10(a) Estimated Closing Cash Amount Section 1.15(a) Estimated Closing Indebtedness Amount Section 1.15(a) Estimated Closing Statement Section 1.15(a) Estimated Closing Third Party Expenses Section 1.15(a) Estimated Closing Working Capital Adjustment Amount Section 1.15(a) Exchange Documents Section 1.9(b) Expense Fund Section 7.6(c) Expense Fund Account Section 7.6(c) Export Approvals Section 2.23 FCPA Section 2.24 Final Closing Statement Section 1.15(c) Financials Section 2.7(a) FIRPTA Compliance Certificate Section 1.4(b)(x) First Merger Recitals GDPR Section 2.12(a)(xiv) HSR Act Section 2.6(b) HIPAA Section 2.12(a)(xiv) Inbound Licenses Section 2.12(d)(i) Indemnification Claim Notice Section 8.3(a7.4(a) Closing Indemnification Claim Objection Notice Section 2.3 Closing Date 7.4(b) Independent Accountant Section 2.3 Company Preamble Company Common Stock 1.15(b) Intellectual Property Rights Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.12(a)(xi) Interested Party Section 2.13 Company Indemnified Parties 2.14(a) Invoice Section 8.2(a)(ii1.4(b)(vi) Contracts Lease Agreements Section 4.8(a2.11(b) Covered Party (PartiesLeased Real Property Section 2.11(b) Letter of Transmittal Section 1.9(a) Material Contract(s) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c2.13(b) Merger Section 2.1 Merger Certificate Section 2.2 Sub I Preamble Merger Sub II Preamble Merger Subs Preamble Mergers Recitals Notice of Adjustment Disagreement Section 1.15(b) Notices Section 5.11(c) OFAC Section 2.23 Open Source Material Section 2.12(a)(xii) Open Source Licenses Section 2.12(a)(xii) Outbound Licenses Section 2.12(d)(ii) Parent Preamble Parent Disclosure Schedule Article V Arrangement Section 2.9(b) Parent Certificate Section 6.3(c) Parent Financial Statements Section 3.5(b) Parent Indemnified Parties Section 8.2(a)(i7.2(a) parties Preamble Payee Parent Prepared Returns Section 8.5 Payor 4.2(a)(ii) Parent SEC Documents Section 8.5 Per Diem Taxes 3.5(a) Parent Stock Issuance Recitals Patent Rights Section 8.7(a2.12(a)(xi) Proceeding Paying Agent Agreement Section 4.17 Royalties 1.4(b)(xv) Payoff Letter Section 2.10(h1.4(b)(vi) Permitted Transferee Section 4.4(b) Personal Data Section 2.12(a)(xiii) Personnel Agreements Section 2.12(f)(i) PNO Section 2.6(b) Post-Closing Deficit Amount Section 1.15(d) Post-Closing Excess Amount Section 1.15(e) Post-Closing Statement Section 1.15(b) Privacy Requirements Section 2.12(a)(xiv) Prohibited Party Lists Section 2.23 PTO Section 2.12(b) Recovered Fraud Amounts Section 7.3(b) Registered IP Section 2.12(a)(xv) Reorg Threshold Section 4.2(f) Representative Losses Section 7.6(b) Resolved Matters Section 1.15(b) Restricted Shares Section 2.2(a) Retained Escrow Amount Section 7.4(f) Retention Pool Section 4.6 Second Certificate of Merger Section 1.2(b) Second Milestone Effective Time Section 2.10(f1.2(b) Second Milestone Payment Amount Merger Recitals Secretary Certificate Section 2.10(f1.4(b)(v) Section 280G Payments Section 5.6(b) Securityholder Representative Preamble Shrink-Wrap Software Section 2.12(a)(xvi) Standard Form Agreements Section 2.12(d)(iii) Stock Portion Section 4.2(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Notice Section 2.12(b4.1(b) Surviving Corporation Section 2.1 1.1(a) Surviving Entity Section 1.1(b) Systems Section 2.12(p) Tax Attribute Section 7.2(c) Technology Section 2.12(a)(xvii) Terminated Agreements Section 5.12 Third Milestone Party Claim Section 2.10(g7.5 Third Party Notice Section 7.5 Top Customers Section 2.25(a) Third Milestone Payment Amount Top Resellers Section 2.10(g2.25(a) Top Suppliers Section 2.25(a) Total Stockholder Consideration Section 4.2(f) Trade Laws ▇▇▇▇▇▇▇ ▇.▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Real Property Holding Corporation Section 2.9(a)(viii) Unresolved Matters Section 1.15(b) Warrant Cancellation Agreement Section 1.4(b)(xii)
Appears in 1 contract
Sources: Merger Agreement (PagerDuty, Inc.)
Terms Defined Elsewhere. The For purposes of this Agreement each of the following is a list of additional terms (capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: 401(k) Plan Section 6.4(d) ADS Cash Consideration Section 2.1(a) ADS Transaction Consideration Section 2.1(a) Affiliate Transaction Section 4.24 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(d) Ancillary Scheme Documentation Section 4.7 Books and Records 3.1(a)(ii) Anti-Takeover Laws Section 2.12(f)(24.22 Broker Fee Section 4.21 CARES Act Section 4.12(c) Claim Notice Cash Consideration Section 8.3(a2.1(a) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.4 Company Preamble Company Common Board Recitals Company Board Recommendation Section 4.2(b) Company Cash-Out Stock Option Section 2.8 2.2(a)(i) Company Disclosure Schedule Letter Article IV Company Expenses Schedule Equity Plan Section 2.13 2.2(a) Company Indemnified Parties Equity Plans Section 8.2(a)(ii2.2(a) Contracts Company ESPP Section 4.8(a2.2(a) Covered Party (PartiesCompany Material Contract Section 4.13(a) Company Organizational Documents Section 8.2(a)(ii4.1(c) Damages Company Real Property Section 8.2(a)(i4.11(b) DGCL Company Registered Intellectual Property Section 2.1 Document Retention Period 4.14(a) Company RSU Section 2.12(f)(22.2(a)(iii) Drug Regulatory Agency Company SEC Documents Section 4.25 4.6(a) Company Securities Section 4.3(e) Company Stock Option Section 2.2(a)(i) Company Systems Section 4.14(j) Company Underwater Option Section 2.2(a)(ii) Confidentiality Agreement Section 6.2(b) Converted Direct Shareholder Section 3.1(a)(xx) Court Documentation Section 3.1(a)(vii) Current Employee Section 6.4(a) CVRs Section 2.1(a) CVR Agreement Recitals DSP Section 4.20(j) Effective Time Section 2.2 1.3 ERISA Section 4.13(a4.17(d) ERISA Affiliate Excluded Benefits Section 4.13(a6.4(a) Finally Determined FCPA Section 8.5(b4.20(j) First Milestone FDA definition of Healthcare Laws Forms of Proxy Section 2.10(e3.1(a)(ii) First Milestone Payment Healthcare Correspondence Section 4.20(b) HHS Section 4.20(e) HSR Act Section 4.5 Indemnified Party Section 6.5(b) Intentional Breach Section 8.5(a) Labor Agreements Section 4.13(a)(ii) Maximum Amount Section 2.10(e6.5(c) Indemnifying Party Measurement Date Section 8.3(a4.3(a) Instrument Non-U.S. Plan Section 2.12(c4.17(h) Merger OECD definition of Good Laboratory Practices OECD Convention Section 2.1 Merger Certificate 4.20(j) OFAC definition of Sanctions Laws Other Required SEC Filing Section 2.2 Merger Sub Preamble 3.1(a)(iii) Outside Date Section 8.2(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Preamble Paying Agent Section 8.2(a)(i2.1(b) parties Payment Fund Section 2.1(b) Pre-Closing Period Section 6.1(a) Privacy Policies Section 4.20(l) Prohibited Payment Section 4.20(j) Proxy Statement Section 3.1(a)(i) Purchaser Preamble Payee Regulatory Authorizations Section 8.5 Payor 4.20(a) Rights Agent Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Section 8.5 Per Diem Taxes 4.10(e) Scheme Document Annex Section 8.7(a3.1(a)(i) Proceeding Securities Act Section 4.17 Royalties 4.6(a) Shareholder Litigation Section 2.10(h6.11 Transaction Consideration Section 2.1(a) Second Milestone Transaction Documentation Section 2.10(f3.1(a)(iv) Second Milestone Payment Amount Treasury Regulations Section 2.10(f2.4 UK Bribery Act Section 4.20(j) Stockholder Consent Voting and Support Agreements Recitals Stockholder Representative Preamble Super Majority WARN Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.19(c)
Appears in 1 contract
Sources: Transaction Agreement (Centessa Pharmaceuticals PLC)
Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Acquisition Sub Preamble Aggregate Loss Threshold Section 8.3(a) Agreement Preamble Biogen Idec License Agreement Available NOL Amount Section 4.7 Biogen Idec Supply Agreement 2.15(c) CIC Amendment Section 4.7 Books and Records Section 2.12(f)(25.14(b) Claim Notice Section 8.3(a8.4(a) Closing Section 2.3 2.3(a) Closing Date Section 2.3 2.3(a) Closing Working Capital Section 2.13(a)(i) Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV III Company Expenses Schedule Intellectual Property Section 2.13 Company Indemnified Parties 3.17(a) Credits Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii2.15(a) Damages Section 8.2(a)(i8.2(a), (c) Decline Date Section 2.13(d) DGCL Section 2.1 Document Retention Period Dispute Notice Section 2.12(f)(28.4(b) Drug Regulatory Agency Disputed Line Items Section 4.25 2.13(d) Dissenting Shares Section 2.16(a) Dissenting Shares Reduction Amount Section 2.16(b) Effective Time Section 2.2 ERISA Equityholder Indemnified Parties Section 4.13(a8.2(b) ERISA Affiliate Estimated Working Capital Section 4.13(a2.13(b) Finally Determined Estimated Working Capital Adjustment Section 8.5(b2.13(b) First Milestone Final Working Capital Adjustment Section 2.10(e2.13(e) First Milestone Payment Amount Form Working Capital Statement Section 2.10(e2.13(a)(i) Indemnifying General Survival Date Section 8.1 Hireworks Section 5.15 Indemnified Officers Section 5.10 Indemnified Party Section 8.3(a8.4(a) Instrument Indemnitor Section 2.12(c8.4(b) Initial Calculation Section 2.13(c) Kenexa Indemnified Parties Section 8.2(a) Kenexa Technology Preamble Labor Union Section 3.16(a)(i) Letter of Transmittal Section 2.10(b) Material Contracts Section 3.6(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Net Adjustment Amount Section 2.13(f) NOL Adjustment Amount Section 2.15(c) NOL Study Section 2.15(b) NOLs Section 2.15(a) Notice of Disagreement Section 2.13(d) Notice of NOL Disagreement Section 2.15(c) Option Cancellation Agreement Section 2.11 Option Holder Section 3.4(c) Outside Date Section 7.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Pre-Closing Taxes Section 5.11(a) Relevant Group Section 3.10(a)(i) Representative Preamble Representative Agreement Section 8.8(a) Representative Parties Section 8.2(a)(i8.8(f)(iii) parties Preamble Payee Settlement Accountants Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f2.13(d) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b3.3(b) Straddle Period Section 5.11(a) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Targeted Credit Amount Section 2.10(g2.15(a) Targeted NOL Amount Section 2.15(a) Tax or Taxes Section 3.10(a)(ii) Tax Return Section 3.10(a)(iii) Terminated Plan Section 3.16(b)(i) Transaction Expense Statement Section 2.9(a) Transfer Taxes Section 3.10(a)(iv)
Appears in 1 contract
Sources: Merger Agreement (Kenexa Corp)
Terms Defined Elsewhere. The following is a list of additional terms used have the meanings set forth in this Agreement and a reference to the Section hereof in which such term is definedSections set forth below: Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.8(b) Available Cash Section 4.7 Books and Records 7.13 Base Premium Section 2.12(f)(27.4(d) Claim Notice Change in Recommendation Section 8.3(a6.2(d) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Board Recitals Company Group Section 2.8 9.2(d) Company Disclosure Schedule Article IV Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.2(b) Confidential Information Section 8.2(a)(ii) Contracts Section 4.8(a10.11(c) Covered Party (PartiesPersons Section 7.4(a) Deposit Agreement Section 8.2(a)(ii3.5 Depositary Section 3.5 Deposited Available Cash Section 7.13 Dissent Notice Section 3.6(b)(ii) Damages Dissent Right Section 8.2(a)(i3.6(b) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.6(a) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.6 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Financing Section 5.6(a) ERISA Affiliate GAAP Section 4.13(a4.6(d) Finally Determined Governmental Entity Section 8.5(b4.5 HKIAC Section 10.8(b) First Milestone HKIAC Rules Section 2.10(e10.8(b) First Milestone Payment Amount Indemnification Agreements Section 2.10(e7.4(a) Indemnifying Party Intervening Event Section 8.3(a6.2(e) Instrument Intervening Event Termination Section 2.12(c6.2(e) Limited Guarantee Recitals Loan Agreement Section 5.6(a) Material Company Permits Section 4.8 Merger Recitals Merger Consideration Section 3.2(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.2(a) Merger Sub Preamble NASDAQ Section 4.2(b) Notice of Recommendation Change Section 6.2(d) Notice Period Section 6.2(d) Option Consideration Section 3.3(a)(i) Parent Preamble Parent Disclosure Group Section 9.2(d) Parent Termination Fee Section 9.2(c) Parties Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 Record ADS Holders Section 6.3(c) Record Date Section 6.3(c) Rollover Agreement Recitals Rollover Shareholders Recitals Ruhnn1106 Section 5.6(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.3(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.6(a) Securities Act Section 8.5 Per Diem Taxes 4.6(a) Share Certificates Section 8.7(a3.2(c)(i) Proceeding Special Committee Recitals Subscription Agreement Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.6(a) Surviving Corporation Company Section 2.1 Third Milestone Takeover Statute Section 2.10(g7.5 Transaction Litigation Section 7.8 Transactions Recitals Uncertificated Shares Section 3.2(c)(i) Third Milestone Payment Amount Vista Section 2.10(g5.6(a)
Appears in 1 contract
Sources: Merger Agreement (Ruhnn Holding LTD)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.09 Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.08(b) Base Premium Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a7.04(d) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Equity Interests Section 2.8 4.02(a) Company Disclosure Schedule Article IV Group Section 9.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(b) Competing Proposal Section 8.2(a)(ii) Contracts Section 4.8(a6.02(d) Covered Party (PartiesPersons Section 7.04(a) Deposit Agreement Section 8.2(a)(ii3.05 Depositary Section 3.05 Dissent Notice Section 3.06(d) Damages Dissent Right Section 8.2(a)(i3.06(d) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.06(a) Dissenting Shares Section 2.12(f)(23.06(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.13(a4.03 Equity Commitment Letter Section 5.05(a) ERISA Affiliate Equity Commitment Letters Section 4.13(a5.05(a) Finally Determined Equity Financing Section 8.5(b5.05(a) First Milestone GAAP Section 2.10(e4.06(b) First Milestone Payment Amount Governmental Entity Section 2.10(e4.05 HKIAC Section 10.08(b) Indemnifying Party HKIAC Rules Section 8.3(a10.08(b) Instrument Indemnification Agreements Section 2.12(c7.04(a) Intervening Event Section 6.02(h) Intervening Event Termination Section 6.02(h) Legal Proceeding Section 5.06 Limited Guarantee Recitals Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.02(a) Merger Sub Preamble Non-Required Remedy Section 7.02(d) NYSE Section 4.02(a) OTC Market Section 4.02(a) Parent Preamble Parent Disclosure Group Section 9.02(d) Parent Termination Fee Section 9.02(c) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 Record ADS Holders Section 6.03(c) Record Date Section 6.03(c) Rollover Agreements Recitals Rollover Shareholders Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.03(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.06(a) Securities Act Section 8.5 Per Diem Taxes 4.06(a) Share Certificates Section 8.7(a3.02(b)(i) Proceeding Special Committee Recitals Superior Proposal Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b6.02(f) Surviving Corporation Company Section 2.1 Third Milestone 2.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 7.05 Transaction Litigation Section 2.10(g7.07 Transactions Recitals Uncertificated Shares Section 3.02(b)(i)
Appears in 1 contract
Sources: Merger Agreement (LAIX Inc.)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Adverse Recommendation Change Section6.02(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2Section6.02(c) Claim Notice Section 8.3(aArbitrator Section10.08(b) Assumed Option Section3.03(b) Base Premium Section7.05(d) Benefit Plan Section4.15(b) BlueCity Holdings Limited Section2.06 Closing Section 2.3 Section2.02 Closing Date Section 2.3 Section2.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Article IV Board Recommendation Recitals Company Expenses Schedule Section 2.13 Equity Interests Section4.02(b) Company Indemnified Parties Section 8.2(a)(iiGroup Section9.02(h) Contracts Section 4.8(aCompany Termination Fee Section9.02(e) Competing Proposal Section6.02(g) Covered Party (PartiesPersons Section7.05(a) Section 8.2(a)(iiDeposit Agreement Section3.05 Depositary Section3.05 Dissenting Shareholders Section3.06(a) Damages Section 8.2(a)(iDissenting Shares Section3.06(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(aSection2.03 Enforceability Exceptions Section4.03 Equity Commitment Letter Section5.05(a) ERISA Affiliate Section 4.13(aEquity Financing Section5.05(a) Finally Determined Section 8.5(bExchange Ratio Section3.03(b) First Milestone Section 2.10(eFinancial Statements Section4.06(b) First Milestone Payment Amount Section 2.10(eHKIAC Section10.08(b) Indemnifying Party Section 8.3(aHKIAC Rules Section10.08(b) Instrument Section 2.12(cIndemnification Agreements Section7.05(a) Insurance Policies Section4.18 Intervening Event Section6.02(e) Legal Proceeding Section5.08 Limited Guarantee Recitals Material Contracts Section4.16(a)(xiv) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Section3.02(a) Merger Consideration Fund Section3.02(a) Merger Sub Preamble Nasdaq Section4.02(c) Non-Required Remedy Section7.02(d) Operating Subsidiary Section4.16(a)(xi) Parent Preamble Parent Disclosure Group Section9.02(h) Parent Termination Fee Section9.02(f) Parties Preamble Party Preamble Paying Agent Section3.02(a) Per ADS Merger Consideration Section3.01(b) Per Share Merger Consideration Section3.01(a) Plan of Merger Section2.03 PRC Subsidiaries Section4.09(a) Proxy Statement Section4.05 Record ADS Holders Section6.04(a) Record Date Section6.04(a) Registrar of Companies Section2.03 Rollover Shareholders Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section4.06(a) Schedule Article V Parent Indemnified Parties Section 8.2(a)(i13E-3 Section6.03(a) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aSEC Documents Section4.06(a) Proceeding Section 4.17 Royalties Section 2.10(hSecurities Act Section4.06(a) Second Milestone Section 2.10(fShare Certificates Section3.02(b)(i) Second Milestone Payment Amount Section 2.10(fSocial Insurance Section4.15(k) Stockholder Consent Special Committee Recitals Stockholder Representative Preamble Super Majority Section 2.12(bSuperior Proposal Section6.02(h) Support Agreement Recitals Surviving Corporation Section 2.1 Third Milestone Section 2.10(gCompany Section2.01 Takeover Statute Section4.23 Tax Returns Section4.13(a) Third Milestone Payment Amount Section 2.10(gTransaction Litigation Section7.08 Transactions Recitals U.S. GAAP Section4.06(b) Uncertificated Shares Section3.02(b)(i) VIE Contracts Section4.09(c)
Appears in 1 contract
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.23(a) Additional Parent Filings Section 5.05(f) Affiliate Transactions Section 3.26(a) Agent Section 7.04(a) Agreed Claims Section 7.03(c) Agreement Preamble Biogen Idec License Agreement Alternative Acquisition Section 4.7 Biogen Idec Supply Agreement 5.01(f) Attorney Section 4.7 Books and Records 7.04(g) Bid Section 2.12(f)(23.19(a) Board Recitals Booked Revenue Section 3.09(e) Bridge Notes Section 2.04(b) Change in Recommendation Section 5.05(f) Claim Notice Section 8.3(a7.04(k) Claim Certificate Section 7.03(a) Closing Section 2.3 2.01(c) Closing Date Section 2.3 2.01(c) Closing Form 8-K Section 5.05(g) Closing Press Release Section 5.05(g) Collateral Source Section 7.02 Communication Policy Section 5.01(h) Company Preamble Company Common Stock Employee Benefit Plan Section 2.8 3.14(a) Company Disclosure Schedule Article IV Government Contract Section 3.19(a) Company Expenses Schedule Government Subcontract Section 2.13 3.19(a) Company Indemnified Parties Group Section 8.2(a)(ii8.15(a) Contracts Company Prepared Returns Section 4.8(a5.04(a) Covered Party (PartiesCompany Unitholder Approval Recitals Control Section 1.01 Copyrights Section 1.01 D&O Beneficiary Section 5.09(b) D&O Claim Section 8.2(a)(ii5.09(b) Damages D&O Provisions Section 8.2(a)(i5.09(a) DGCL Data Room Section 2.1 Document Retention Period 8.05 Deductible Section 2.12(f)(27.01(b) Drug Regulatory Agency Deposit Materials Section 4.25 2.02(b) Director Nomination Agreement Section 2.04(b) DLLCA Recitals Earn Out Shares Section 2.06(a) Effective Time Section 2.2 ERISA 2.01(d) Environmental Permits Section 4.13(a3.17 Eos Companies Interim Financial Statements Section 3.04(a) ERISA Affiliate Escrow Agent Section 4.13(a2.04(b) Finally Determined Excluded Units Section 8.5(b2.02(a)(ii) Financial Statements Section 3.04(a) First Milestone Certificate of Merger Section 2.10(e2.01(d) First Milestone Payment Amount Merger Recitals First Surviving Company Recitals Formula Section 2.10(e2.02(b) Indemnified Matters Section 7.01(a) Indemnified Persons Section 5.09(a) Indemnifying Party Section 8.3(a7.03(c) Instrument Intended Tax Treatment Recitals Internal Controls Section 2.12(c3.04(a) Merger IRS Section 2.1 Merger Certificate 3.14(a) Latest Balance Sheet Section 2.2 3.04(a) LTIP Section 5.01(e) Material Customer Section 3.09(c) Material Contract Section 3.09(b) Mergers Recitals Merger Sub I Preamble Merger Sub II Preamble New Customer Contracts Section 3.09(a) Newco Section 5.14(a) Newco Merger Sub Section 5.14(a) Non-Party Affiliate Section 5.11 Obligations Section 7.04(a) Ordinary Course of Business Section 8.05 Outside Date Section 6.01(c) Parent Preamble Parent Disclosure Schedule Article V Class A Common Section 4.05(a) Parent Indemnified Class B Common Section 4.05(a) Parent Warrants Section 4.05(a) Parent SEC Reports Section 4.08 Parent Stockholder Group Section 8.15 Party Preamble Patents Section 1.01 Permits Section 3.16(b) Pledged Collateral Section 7.04(a) Pledged Shares Section 7.04(a) Pledgor Section 7.04(a) Pre-Closing Period Section 5.01(a) Pre-Closing Reorganization Section 5.14(a) Privileged Communications Section 8.15 Purchaser Indemnitees Section 7.01(a) Registration Rights Agreement Section 2.04(b) Second Certificate of Merger Section 2.01(d) Second Effective Time Section 2.01(d) Second Merger Recitals Securityholder Representative Preamble Signing Press Release Section 5.05(b) Sponsor Section 2.04(b)(x) Sponsor Earn Out Agreement Section 2.04(b)(x) Trademarks Section 1.01 Transfer Taxes Section 5.04(e) Triggering Event Section 2.06(a) UCC Section 7.04(b) Ultimate Surviving Company Recitals Unitholder Letter of Transmission Section 2.03(b) Waiving Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)8.15
Appears in 1 contract
Sources: Agreement and Plan of Merger (B. Riley Principal Merger Corp. II)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.08(b) Base Premium Section 4.7 Books and Records 7.04(d) Change in Recommendation Section 2.12(f)(2) Claim Notice Section 8.3(a6.02(f) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Equity Interests Section 2.8 4.02(a) Company Disclosure Schedule Article IV Group Section 9.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(b) Competing Proposal Section 8.2(a)(ii6.02(e) Contracts Competition Laws Section 4.8(a4.05 Covered Persons Section 7.04(a) Covered Party (Parties) Deposit Agreement Section 8.2(a)(ii) Damages 3.05 Depositary Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.05 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.13(a4.03 GAAP Section 4.06(b) ERISA Affiliate Governmental Entity Section 4.13(a4.05 HKIAC Section 10.08(b) Finally Determined HKIAC Rules Section 8.5(b10.08(b) First Milestone Indemnification Agreements Section 2.10(e7.04(a) First Milestone Payment Amount Intervening Event Section 2.10(e6.02(h) Indemnifying Party Intervening Event Termination Section 8.3(a6.02(h) Instrument Legal Proceeding Section 2.12(c5.06 Limited Guarantee Recitals Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.02(a) Merger Sub Preamble NASDAQ Section 4.02(a) Non-Required Remedy Section 7.02(e) Option Consideration Section 3.03(a) Parent Preamble Parent Disclosure Group Section 9.02(d) Parent Termination Fee Section 9.02(c) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 Record ADS Holders Section 6.03(c) Record Date Section 6.03(c) Rollover Agreement Recitals Rollover Shareholders Recitals RSU Consideration Section 3.03(c) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.03(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.06(a) Securities Act Section 8.5 Per Diem Taxes 4.06(a) Special Committee Recitals Superior Proposal Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b6.02(g) Surviving Corporation Company Section 2.1 Third Milestone 2.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 7.05 Transaction Litigation Section 2.10(g7.07 Transactions Recitals Uncertificated Shares Section 3.02(b)(i)
Appears in 1 contract
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: ACA Section 4.15(c) Additional Buyer Filings Section 8.10(f) Affiliated Transactions Section 4.19 Agreement Preamble Biogen Idec License Agreement Allocation Section 4.7 Biogen Idec Supply Agreement 4.19 Audited Financial Statements Section 4.7 Books and Records 4.4(a)(i) Blocker Affiliated Transactions Section 2.12(f)(25.8 Blocker Bring-Down Certificate Section 11.2(b)(iii) Claim Notice Blocker Certificates of Merger Section 8.3(a2.2(b) Blocker Dissenting Shareholders Section 3.6 Blocker Dissenting Shares Section 3.6 Blocker Effective Time Section 2.2(b) Blocker Letter of Transmittal Section 3.5(a) Blocker Merger Closing Section 2.2(a) Blocker Merger Sub 1 Preamble Blocker Merger Sub 2 Preamble Blocker Merger Sub 3 Preamble Blocker Merger Subs Preamble Blocker Mergers Recitals Blockers Preamble Buyer Preamble Buyer Balance Sheet Section 6.10(c) Buyer Bring-Down Certificate Section 11.3(d) Buyer Contribution Amount Section 2.4(c) Buyer Parties Preamble Buyer Preferred Stock Section 6.3(a) Buyer Public Securities Section 6.9 Buyer SEC Documents Section 6.8(a) Buyer Warrants Section 6.3(a) Cancelled Equity Interests Section 3.1(d) CBA Section 4.9(a)(i) Certificates of Merger Section 2.2(c) Closing Section 2.3 2.2(a) Closing Date Section 2.3 2.2(a) Closing Form 8-K Section 8.10(g) Closing Press Release Section 8.10(g) Company Preamble Company Common Stock A&R LLCA Recitals Company Bring-Down Certificate Section 2.8 11.2(a)(iv) Company Disclosure Schedule Article IV Certificate of Merger Section 2.2(c) Company Expenses Schedule Merger Recitals Company Merger Closing Section 2.13 2.1(a) Company Indemnified Parties Merger Sub Preamble Company Unitholder Letter of Transmittal Section 8.2(a)(ii4.3(a) Contracts Competing Buyer Section 4.8(a8.21(a) Covered Party (PartiesData Room Section 13.5 Delaware Corporation Section 8.22 DGCL Recitals DLLCA Recitals D&O Provisions Section 8.13(a) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.2(c) EIP Section 4.13(a8.3(c) ERISA Affiliate Environmental Permits Section 4.13(a4.18 ESPP Section 8.4(b) Finally Determined Estimated Blocker Closing Statement Section 8.5(b3.2(c) First Milestone Estimated Company Closing Statement Section 2.10(e3.2(a) First Milestone Payment Execution Date Preamble Failed Blocker Merger Section 2.2(a) Financial Statements Section 4.4(a) Foreign Plan Section 4.15(e) Group Company Processor Section 4.10(h) Indemnified Persons Section 8.13(a) Insurance Policies Section 4.16 Intended Tax Treatment Section 10.1(e) Internal Controls Section 4.4(c) IRS Section 4.15(a) IVP Blocker Preamble IVP Blocker Merger Preamble JOBS Act Section 8.3(b) KPCB Blocker Preamble KPCB Blocker Merger Recitals Material Contract Section 4.9(b) Mergers Recitals Merger Subs Preamble New Equity Plans Section 8.4(b) Outside Date Section 12.1(c) Parties Preamble Party Preamble PCAOB Financial Statements Section 8.10(h) Permits Section 4.17(b) Permitted Equity Financing Proceeds Section 8.15(b)(i) PIPE Investment Recitals PIPE Investors Recitals Pre-Closing Period Section 7.1 Premium Cap Section 8.13(b)(ii) Recipient Section 1.1 Registration Rights Agreement Recitals Rollover Option Section 3.1(c)(iii) Rollover Warrant Section 3.1(c)(iv) Sale Section 10.1(e) Signing Form 8-K Section 8.10(b) Signing Press Release Section 8.10(b) Sponsor Side Letter Recitals Standard Form Agreements Section 4.10(d) Subscription Agreements Recitals Surviving Company Section 2.1(e) Surviving IVP Merger Sub Section 2.1(b) Surviving KPCB Merger Sub Section 2.1(a) Surviving Merger Subs Section 2.1(c) Surviving W Capital Merger Sub Section 2.1(c) Tail Policy Section 8.13(b)(ii) Tax Positions Section 10.1(g) Tax Receivable Agreement Recitals Trade Controls Section 4.20(a) Transaction Litigation Section 8.20 Transaction Support Agreement Recitals Trust Amount Section 2.10(e6.7 Trust Distributions Section 13.9 Unaudited Balance Sheet Section 4.4(a)(ii) Indemnifying Party Unaudited Financial Statements Section 8.3(a4.4(a)(ii) Instrument Unitholder Materials Section 2.12(c3.5(b) W Capital Blocker Recitals W Capital Blocker Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)Recitals
Appears in 1 contract
Sources: Business Combination Agreement (Thayer Ventures Acquisition Corp)
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: A&R GGPPA Section 6.1(f) Acquired Entity Benefit Plan Section 3.14(a) Affiliate Transaction Section 3.21 Agreement Preamble Biogen Idec License Agreement Antitrust Laws Section 4.7 Biogen Idec Supply Agreement 6.2(c) Balance Sheet Date Section 4.7 Books and Records 3.5(a) Buyers Preamble Carlsbad CIV Preamble Casualty Loss Section 2.12(f)(2) Claim Notice Section 8.3(a) 6.4 Closing Section 2.3 2.4 Closing Date Section 2.3 Company 2.4 control Section 1.1 D&O Provisions Section 6.10(a) ECP III Preamble Company Common Stock ECP III CIV Preamble ECP III-A Preamble ECP III-B Preamble ECP III-C Preamble ECP Parties Preamble Excess Payment Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.3(f)(i) Final Adjustment Certificate Section 2.13 Company 2.3(d) Final Settlement Date Section 2.3(c) Financial Statements Section 3.5(a) First Lien Debt Payoff Amount Section 2.5(b)(iii)(C) General Partner Preamble GP Buyer Preamble GP Interests Recitals Guarantee Section 8.14(a) Guarantor Preamble Holdings Recitals Indemnified Persons Section 6.10(a) Intended Tax Treatment Section 2.6(a) ▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ Section 8.11(a) LP Buyer Preamble LP Interest Sellers Preamble LP Interests Recitals Material Contract Section 3.10(b) Maximum D&O Premium Section 6.10(a) MOP Section 6.1(f) Multiemployer Plan Section 3.14(a) New Plans Section 6.13 Non-Continuing Employee Section 6.13 Nonparty Affiliates Section 6.17 Notice of Disagreement Section 2.3(c) Outside Date Section 7.1(c) Partnership Preamble Partnership Proprietary Rights Section 3.11(a) Party and Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Preamble Purchase Price Section 2.2 ERISA Purchase Price Allocation Section 4.13(a2.6(b) ERISA Affiliate R&W Insurance Policy Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment 6.3 Second Lien Debt Payoff Amount Section 2.10(e2.5(b)(iii)(D) Indemnifying Party Seller Representative Section 8.3(a8.13(a) Instrument Seller Representative Expense Account Section 2.12(c8.13(c) Merger Seller Tax Returns Section 2.1 Merger Certificate 6.5(a) Sellers Preamble Sendero Carlsbad Finance Recitals Sendero Carlsbad Midstream Recitals Sendero Management Preamble Shortfall Payment Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties 2.3(f)(i) Subject Interests Recitals Tail Policy Section 8.2(a)(i6.10(a) parties Preamble Payee Tax Contest Section 8.5 Payor Section 8.5 Per Diem 6.5(c) Transfer Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g6.5(f)
Appears in 1 contract
Sources: Equity Purchase Agreement (Crestwood Equity Partners LP)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 5.07(d) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.03(d)(i) Book-Entry Shares Section 4.7 Books and Records 2.02(b) Capitalization Date Section 2.12(f)(23.02(a) Claim Notice Certificate of Merger Section 8.3(a1.02 Certificates Section 2.02(b) Change of Board Recommendation Section 5.03(a)(iv) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Board Recommendation Recitals Company Disclosure Schedule Article IV III Company Expenses Schedule Employees Section 2.13 5.07(a) Company Indemnified Parties Financial Statements Section 8.2(a)(ii3.07(a) Contracts Company Material Contract Section 4.8(a3.13(a) Covered Party (PartiesCompany Permits Section 3.05(a) Company Preferred Stock Section 8.2(a)(ii3.02(a) Damages Company Representatives Section 8.2(a)(i5.02(a) Company SEC Documents Section 3.06(a) Company Stockholder Approval Section 3.21 Confidentiality Agreement Section 5.02(c) D&O Indemnification Agreements Section 5.08(a) D&O Runoff Insurance Section 5.08(c) DGCL Recitals Dispute Section 2.1 Document Retention Period 3.15(l) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.03 Effective Time Section 2.2 ERISA 1.02 Electronic Delivery Section 4.13(a8.13 Employment Practices Section 3.12(a) ERISA Affiliate Export Approvals Section 4.13(a3.05(e) Finally Determined Fundamental Representations Section 8.5(b6.02(a)(ii) First Milestone Guaranteed Obligations Section 2.10(e8.15(a) First Milestone Payment Guarantor Section 8.15(a) Guaranty Section 8.15(c) Indemnified Persons Section 5.08(a) Independent Director Section 3.12(f) Insurance Policies Section 3.17 Intercompany Contracts Section 3.13(a)(vii) Intervening Event Notice Period Section 5.03(e)(i) Leased Real Property Section 3.18(c) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.08(c) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Recitals Merger Sub Preamble Most Recent Balance Sheet Section 3.09(a)(i) New Plans Section 5.07(a) Parent Preamble Parent Disclosure Schedule Article V Representatives Section 5.02(a)(i) Parent Indemnified Parties Subsidiary Section 8.2(a)(i4.03(a) parties Preamble Payee Parent Welfare Plan Section 8.5 Payor 5.07(a) Paying Agent Section 8.5 Per Diem Taxes 2.02(a) Proxy Statement Section 8.7(a1.03(a) Proceeding PSU Award Section 4.17 Royalties 2.04(d) Replacement PSU Section 2.10(h2.04(d) Second Milestone Replacement RSU Section 2.10(f2.04(b) Second Milestone Payment Amount RSU Award Section 2.10(f2.04(b) Stockholder Consent ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 3.06(a) Section 16 Section 5.10 Shares Recitals Stockholder Representative Preamble Super Majority Significant Customer Section 2.12(b3.13(a)(xviii) Specified Antitrust Laws Section 6.01(b) Special Meeting Section 1.03(e) Superior Proposal Notice Period Section 5.03(d)(i) Surviving Corporation Recitals Takeover Law Section 2.1 Third Milestone 3.03(b) Termination Fee Section 2.10(g7.02(b) Third Milestone Payment Amount U.S. Continuing Employees Section 2.10(g5.07(b) WARN Act Section 3.12(d)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.4(a) Action Section 5.14 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Bankruptcy Exception Section 2.12(f)(25.3(a) Claim Board Appointment Date Section 2.4(a) Book-Entry Shares Section 4.2(b) Certificates Section 4.2(b) CFIUS Notice Section 8.3(a) 7.19 Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recitals Company Board Recommendation Section 2.3(a)(v) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Article IV Documents Section 5.10(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.7(b) Contracts Company Intellectual Property Section 4.8(a5.16 Company Material Contract Section 5.13(a) Covered Party (PartiesCompany Plan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document Retention Period 7.4(a) Company SEC Filings Section 2.12(f)(25.7(a) Drug Regulatory Agency Company Shareholder Approval Section 4.25 5.3(b) Company Shareholders Recitals Company Shareholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.23 Continuing Directors Section 2.4(a) Determination Notice Section 7.5(d)(i)(C) Dissenting Shareholder Section 4.3 Dissenting Shares Section 4.3 Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.23 End Date Section 9.1(b)(i) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone Expiration Date Annex A FCPA Section 2.10(e5.6(b) First Milestone Payment Governmental Antitrust Entity Section 7.6(e)(i) Indemnified Parties Section 7.13(a) Independent Directors Section 2.4(b) Intervening Event Change of Recommendation Section 7.5(d)(ii) Investments Section 5.2(d) IRS Section 5.11(b) Loan Payoff Amount Section 2.10(e7.7(b) Indemnifying Party Measurement Date Section 8.3(a) Instrument Section 2.12(c5.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble MGBCL Recitals Minimum Condition Section 2.1(b) Notes Section 7.7(a) Notice Period Section 7.5(d)(i)(C) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Offer to Purchase Section 2.1(g) Parent Preamble Parent Disclosure Schedule Documents Section 6.7(b) Parent Representatives Section 7.4(a) Party, Parties Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Recent SEC Reports Article V Parent Indemnified Parties Redemption Section 8.2(a)(i7.7(a) parties Preamble Payee Schedule TO Section 8.5 Payor 2.1(g) Schedule 14D-9 Section 8.5 Per Diem Taxes 2.3(b) Short-Form Threshold Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) 7.3 Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.13(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)2.3(a)(iv) Top-Up Option Section 2.2(a) Transaction Litigation Section 7.8 WARN Act Section 5.12
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 280G Approval Section hereof in which such term is defined: 5.7(b) 280G Waiver Section 5.7(a) 401(k) Plan Section 5.12 Acquired Company Licensed IP Section 2.10(a) Acquired Company Registered IP Section 2.10(a) Adjustment Resolution Period Section 1.17(c) Adjustment Review Period Section 1.17(c) Advisory Group Section 9.2(b) Agreement Preamble Biogen Idec License Agreement Date Preamble Alternative Arrangements Section 4.7 Biogen Idec Supply Agreement 7.3(f) Anti-Corruption Laws Section 4.7 2.22(a) Balance Sheet Date Section 2.6(b) Board Recitals Books and Records Section 2.12(f)(22.15(b) Cancelled Shares Section 1.9(d) Certificate of Incorporation Section 2.1(d) Certificate of Merger Section 1.2(a) Certificates of Merger Section 1.2(b) Charter Documents Section 2.1(d) Closing Section 1.4(a) Closing Date Section 1.4(a) Closing Statement Section 1.17(b) Company Preamble Company Audited Financial Statements Section 2.6(a) Company Authorizations Section 2.13 Company Board Resolutions Section 2.3(a) Company Group Section 9.17 Company Indemnitees Section 4.6(a) Company Interim Financial Statements Section 2.6(a) Company Stockholder Approval Recitals Company Stockholder Consent Recitals Confidentiality Agreement Section 5.18 Continuing Claim Section 7.4(e) Contributor Section 2.10(h) Current Balance Sheet Section 2.6(b) D&O Indemnifiable Matters Section 4.6(a) D&O Tail Policy Section 4.6(b) Deductible Amount Section 7.3(a) Deficiency Amount Section 1.17(e) Delaware LLC Act Section 1.1 Determination Date Section 1.17(d) DGCL Section 1.1 Director and Officer Resignation Letter Section 1.4(b)(ii) Disclosure Schedule Article II Dissenting Shares Section 1.13(a) DOJ Section 5.10(a) Effective Time Section 1.2(a) Embargoed Countries Section 2.21 End Date Section 8.1(b) Estimated Closing Cash Amount Section 1.17(a) Estimated Closing Indebtedness Amount Section 1.17(a) Estimated Closing Statement Section 1.17(a) Estimated Closing Third Party Expenses Section 1.17(a) Estimated Closing Working Capital Adjustment Amount Section 1.17(a) Excess Amount Section 1.17(f) Exchange Documents Section 1.11(b)(ii) Expense Fund Section 9.2(c) Export Approvals Section 2.21 FCPA Section 2.22(a) Final Closing Statement Section 1.17(d) Financials Section 2.6(a) FIRPTA Compliance Certificate Section 1.4(b)(x) First Merger Recitals First-Step Surviving Corporation Section 1.1 FTC Section 5.10(a) Healthcare Laws Section 2.20(g) Inbound Licenses Section 2.10(f) Indemnification Claim Notice Section 8.3(a7.4(a) Closing Indemnification Claim Objection Notice Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses 7.4(b) Indemnification Schedule Section 2.13 Company 4.6(a) Indemnified Parties Section 8.2(a)(ii7.2(a) Contracts Indemnifying Parties Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.2(a) Indemnifying Party Section 8.3(a7.2(a) Instrument Independent Accountant Section 2.12(c1.17(c) Intended Tax Treatment Recitals Interested Party Section 2.12 Interim Period Section 5.1 Invoice Section 5.16 IP Agreement Section 2.10(h) Joinder and Lock-Up Agreement Section 1.4(b)(ix) Key Supplier Section 2.23 Lease Agreements Section 2.9(b) Leased Real Property Section 2.9(b) Letter of Transmittal Section 1.11(b)(i) Lock-Up Legend Section 4.4(b) Loss Section 7.2(a) Material Contract Section 2.11(a) Measuring Period Section 1.14(b) Merger Section 2.1 Merger Certificate Section 2.2 Sub I Preamble Merger Sub II Preamble Merger Subs Preamble Mergers Recitals New Plans Section 5.11(b) Non-Continuing Employee Release Section 5.18 Notice of Adjustment Disagreement Section 1.17(c) Notices Section 5.13 OFAC Section 2.21 Option Release Agreements Section 5.17 Option Release Individual Section 2.2(f) Outbound Licenses Section 2.10(f) Parent Preamble Parent Disclosure Schedule Article V III Parent Indemnified Financial Statements Section 3.12(b) Parent Parties Section 8.2(a)(i9.15 Parent Prepared Returns Section 4.2(a)(ii) parties Preamble Payee Parent Stock Issuance Recitals Permitted Actions Section 8.5 Payor 5.15.1 Press Release Section 8.5 Per Diem Taxes 5.9 Privacy Requirements Section 8.7(a2.10(a) Proceeding Prohibited Party Lists Section 4.17 Royalties 2.21 Prospectus Section 2.10(h4.4(b) Registrable Securities Section 4.4(b) Registration Statement Section 4.4(b) Resolved Matters Section 1.17(c) Representative Losses Section 9.2(b) Restraint Section 6.1(a) Restrictive Covenant Agreement Recitals Retained Holdback Amount Section 7.4(e) Retained Milestone Payments Section 7.4(b) Rule 144 Section 4.4(g) Second Milestone Certificate of Merger Section 2.10(f1.2(b) Second Milestone Payment Effective Time Section 1.2(b) Second Merger Recitals Securities Act Legend Section 4.4(e) Selling Stockholder Questionnaire 4.4(h) Spinoff Plan Section 5.12 Specified Non-Continuing Employee Amount Section 2.10(f5.18 Spreadsheet Section 4.3 Statement No. 5 Section 2.6(d) Stockholder Consent Recitals Notice Section 4.1(a) Stockholder Representative Preamble Super Majority Stockholder Representative Engagement Agreement Section 2.12(b9.2(b) Stockholder Representative Group Section 9.2(b) Survival Date Section 7.1 Surviving Corporation Entity Section 2.1 Third Milestone 1.1 Tax Section 2.10(g2.8(a)(i) Tax Contest Section 4.2(c) Tax Refunds Section 4.2(f) Tax Return Section 2.8(a)(ii) Taxes Section 2.8(a)(i) Terminated Agreements Section 1.4(b)(ii) Third Milestone Payment Amount Party Claim Section 2.10(g7.5 Third Party Notice Section 7.5 Trade Laws Section 2.21 Transaction Communication Section 9.17 Unresolved Matters Section 1.17(c) Unresolved Setoff Claims Section 7.4(b) U.S. Data Security Program Section 2.10(a) Waived 280G Benefits Section 5.7(a)
Appears in 1 contract
Sources: Agreement and Plan of Merger and Reorganization (Mirum Pharmaceuticals, Inc.)
Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: ACA Section 4.15(c) Additional Buyer Filings Section 8.10(f) Affiliated Transactions Section 4.20 Aggregate Consideration Section 10.1(e) Agreement Preamble Biogen Idec License Agreement Allocation Section 10.1(e) Alternative Financing Section 4.7 Biogen Idec Supply Agreement 8.13(a)(iv) Antitrust Laws Section 8.8(c) Assets Section 4.19 Audited Financial Statements Section 4.4(a)(i) Blocker Affiliated Transactions Section 5.9 Blocker Bring-Down Certificate Section 4.7 Books and Records 11.2(d) Blocker Certificates of Merger Section 2.2(b) Blocker Effective Time Section 2.2(b) Blocker Letter of Transmittal Section 3.4(a) Blocker Merger Closing Section 2.2(a) Blocker Merger Sub 1 Preamble Blocker Merger Sub 2 Preamble Blocker Merger Sub 3 Preamble Blocker Merger Sub 4 Preamble Blocker Merger Sub 5 Preamble Blocker Merger Sub 6 Preamble Blocker Merger Subs Preamble Blocker Mergers Recitals Blocker Owned Company Equity Interests Section 5.4(b) Blockers Preamble Buyer Preamble Buyer Balance Sheet Section 6.11(c) Buyer Bring-Down Certificate Section 2.12(f)(211.3(c) Claim Notice Buyer Certificate of Merger Section 2.2(c) Buyer Certificates of Merger Section 2.2(c) Buyer Contribution Amount Section 3.2(e)(i) Buyer Effective Time Section 2.2(c) Buyer Merger Closing Section 2.2(a) Buyer Mergers Recitals Buyer Parties Preamble Buyer Preference Shares Section 6.3(a) Buyer Public Securities Section 6.9 Buyer SEC Documents Section 6.8(a) Buyer Warrants Section 6.3(a) Cancelled Equity Interests Section 3.1(d) Cancelled Cash Portion Section 8.3(a3.1(c)(iii)(B) Cancelled Option Value Section 3.1(c)(iii)(B) CBA Section 4.9(a)(i) Certificates of Merger Section 2.2(d) Closing Section 2.3 Section 2.2(a) Closing Cash Section 3.5(a) Closing Date Section 2.2(a) Closing Form 8-K Section 8.10(g) Closing Net Working Capital Section 3.5(a) Closing Press Release Section 8.10(g) Closing Statement Section 3.5(a) Closing Transaction Expenses Section 3.5(a) Commitment Letter Section 2.3 8.13(a)(i) Company Preamble Company Common Stock A&R LLCA Recitals Company Bring-Down Certificate Section 2.8 11.2(d) Company Disclosure Schedule Article IV Certificate of Merger Section 2.2(d) Company Expenses Schedule Section 2.13 Equity Interests Section 4.3(a) Company Indemnified Parties Section 8.2(a)(iiMerger Section 2.2(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Company Merger Closing Section 2.2 ERISA Section 4.13(a(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Company Merger Sub Preamble Parent Company Optionholder Letter of Transmittal Section 3.4(a) Company Unitholder Letter of Transmittal Section 3.4(a) Competing Buyer Section 8.23 Contribution Common Units Section 3.2(e)(i)(A) Control Section 1.1 D&O Provisions Section 8.14(a) Data Room Section 13.5 Debt Financing Section 8.13(a)(i) Debt Financing Sources Section 8.13(a)(i) Debt Payoff Amount Section 3.2(e)(i)(A) DGCL Recital Disclosing Party Section 1.1 Dispute Notice Section 3.5(b) DLLCA Recitals Domestication Recitals E2open Intermediate Section 4.4(e) Effective Date Preamble Parent Disclosure Schedule Article V Parent Effective Time Section 2.2(d) EALP Section 1.1 EIP Section 8.4 EILP Section 1.1 ▇▇▇▇▇▇▇ Catch-Up Amount 3.2(e)(i)(E) ▇▇▇▇▇▇▇ Eagle Blocker Preamble ▇▇▇▇▇▇▇ Merger Recitals ▇▇▇▇▇▇▇ Note Transfer Section 3.2(f) ▇▇▇▇▇▇▇ Reorganization Transferee Section 8.26 Environmental Permits Section 4.17 Equity Financing Section 1.1 Equityholder Materials Section 3.4(b) Equityholder Representative Preamble Estimated Closing Blocker Indebtedness Section 3.2(b)(i) Estimated Closing Statement Section 3.2(b)(ii) Estimated Merger Consideration Section 3.2(b)(ii) Final Allocation Section 10.1(e) Final Closing Blocker Indebtedness Section 3.5(a) Final Closing Company Indebtedness Section 3.5(a) Final Tax Basis Balance Sheet Section 10.1(e) Financial Statements Section 4.4(a) Foreign Plan Section 4.15(f) Forward Purchase Agreement Recitals Forward Purchase Amount Recitals ▇▇▇▇▇ Payoff Letter Section 3.2(e)(ii)(D) Indemnified Parties Persons Section 8.14(a) Insight Agreement Section 8.2(a)(i3.6(m) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Insight Catch-Up Amount Section 2.10(f3.2(e)(i)(E) Stockholder Consent Insight Cayman Blocker Preamble Insight Cayman Merger Recitals Stockholder Representative Insight Delaware Blocker Preamble Super Majority Insight Delaware Merger Recitals Insight GBCF Cayman Blocker Preamble Insight GBCF Cayman Merger Preamble Insight GBCF Delaware Blocker Preamble Insight GBCF Delaware Merger Recitals Insight Blocker Letter Agreement Section 2.12(b3.7(f) Insight Letter Agreement Section 3.6(m) Insurance Policies Section 4.15(b) Intended Tax Treatment Section 10.1(e) Internal Controls Section 4.4(c) Investor Rights Agreement Recitals IRS Section 4.15(a) LLCA Amendment and Restatement Section 3.1(e) Lock-Up Agreement Recitals Material Contract Section 4.9(b) Material Customer Section 4.9(c) Material Leases Section 4.7 Maximum Payable Amount Section 8.15(d) Merger Consideration Section 3.2(a) Mergers Recitals NBOKS Recitals NBOKS Side Letter Recitals New Commitment Letter Section 8.13(a)(iv) Non-Party Affiliate Section 13.14 Outside Date Section 12.1(c) Parties Preamble Party Preamble PCAOB Financial Statements Section 8.10(h) PDI Blocker Preamble PDI Merger Recitals Permits Section 4.17(b) Permitted Equity Financing Proceeds Section 8.15(c) PIPE Investment Recitals PIPE Investors Recitals Pre-Closing Period Section 7.1 Pre-Closing Reorganization Section 8.26 Premium Cap Section 8.14(b)(ii) Recipient Section 1.1 Resolution Period Section 3.5(b) Review Period Section 3.5(b) Sale Section 10.1(e) Sellers Prepared Returns Section 10.1(a) Signing Form 8-K Section 8.10(b) Signing Press Release Section 8.10(b) Sponsor Side Letter Recitals Subscription Agreements Recitals Support Agreement Section 8.12 Surviving Blocker Section 2.1(g) Surviving Corporation Section 2.1 Third Milestone Section 2.10(gBlocker Interests Section 3.1(a)(i) Third Milestone Payment Surviving Buyer Section 2.1(h) Surviving Company Section 2.1(i) Surviving ▇▇▇▇▇▇▇ Eagle Blocker Section 2.1(f) Surviving Insight Cayman Blocker Section 2.1(a) Surviving Insight Delaware Blocker Section 2.1(c) Surviving Insight GBCF Cayman Blocker Section 2.1(d) Surviving Insight GBCF Delaware Blocker Section 2.1(e) Surviving PDI Blocker Section 2.1(g) SVB Payoff Amount Section 2.10(g)3.2(e)(i)(B) SVB Payoff Letter Section 3.2(e)(i)(A) Tail Policy Section 8.14(b)(ii) Tax Accounting Firm Section 10.1(e) Tax Basis Balance Sheet Section 10.1(e) Tax Contest Section 10.1(i) Tax Positions Section 10.1(g) Tax Receivable Agreement Recitals Total Individual Blocker Merger Consideration Section 3.1(a)(ii) Total Individual Company Optionholder Merger Consideration Section 3.1(c)(iii) Total Individual Company Class A Unitholder Merger Consideration Section 3.1(c)(ii) Total Individual Company Class B Unitholder Merger Consideration Section 3.1(c)(iii) Trade Controls Section 4.21(a) Transaction Expenses Amount Section 3.2(e)(i)(B) Trust Amount Section 6.7 Trust Distributions Section 13.9 Unaudited Balance Sheet Section 4.4(a)(ii) Unaudited Financial Statements Section 4.4(a)(ii) Valuation Firm Section 3.5(b) Waived 280G Benefits Section 8.17
Appears in 1 contract
Sources: Business Combination Agreement (CC Neuberger Principal Holdings I)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Action Section 4.14(a) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2Section 6.4(c)(ii) Claim Notice Section 8.3(aArticles of Merger Section 2.3 Bankruptcy Exception Section 4.3(a) Certificates Section 3.2(b) Closing Section 2.3 Section 2.2 Closing Date Section 2.3 Section 2.2 Company Preamble Company Common Stock Section 2.8 Adverse Recommendation Change Section 6.4(c)(i) Company Board Recommendation Section 4.3(d) Company Disclosure Schedule Article IV Documents Section 4.10(a) Company Expenses Schedule Section 2.13 Financial Advisor Section 4.3(c) Company Indemnified Parties Section 8.2(a)(iiFinancial Statements Section 4.7(b) Contracts Section 4.8(aCompany Intellectual Property Section 4.16(a) Covered Party (PartiesCompany Material Contract Section 4.13(a) Section 8.2(a)(iiCompany Plan(s) Damages Section 8.2(a)(iSection 4.11(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2Company Preferred Stock Section 4.2(a) Drug Regulatory Agency Section 4.25 Company Representatives Section 6.3(a) Company SEC Filings Section 4.7(a) Company Shareholder Approval Section 4.3(b) Company Shareholders Recitals Company Shareholders’ Meeting Section 6.2(c) Company Subsidiary Section 4.1 Determination Notice Section 6.4(d)(i)(C) Effective Time Section 2.2 Section 2.3 End Date Section 8.1(b)(i) ERISA Section 4.13(aSection 4.11(a) ERISA Affiliate Section 4.13(aSection 4.11(a) Finally Determined Section 8.5(bExchange Fund Section 3.2(a) First Milestone Section 2.10(eImprovements Section 4.19(c) First Milestone Payment Amount Section 2.10(eIndemnified Parties Section 6.11(a) Indemnifying Party Section 8.3(aIntervening Event Change of Recommendation Section 6.4(d)(ii) Instrument Section 2.12(cInvestments Section 4.2(d) IRS Section 4.11(b) Measurement Date Section 4.2(a) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Section 3.1(a) Merger Sub Preamble Multiemployer Plan Section 4.11(c) Notice Period Section 6.4(d)(i)(C) OFAC Section 1.1(v) Parent Preamble Parent Disclosure Schedule Article V Expenses Section 8.2(c) Parent Indemnified Parties Section 8.2(a)(iRepresentatives Section 6.3(a) parties Party Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aPaying Agent Section 3.2(a) Proceeding Section 4.17 Royalties Section 2.10(hPerformance Awards Section 3.5(d) Second Milestone Section 2.10(fProxy Statement Section 6.2(a) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(bRecent SEC Reports Article IV Rollover Option Section 3.5(b) Surviving Corporation Section Section 2.1 Third Milestone Section 2.10(gTail Period Section 6.11(c) Third Milestone Payment Amount Section 2.10(g)Takeover Provisions Section 4.21(a) TBCA Recitals Transaction Litigation Section 6.6 WARN Act Section 4.12
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section Article hereof in which such term is defined: Actual Closing Balance Sheet Section 3.4(d) Actual Closing Date Cash Section 3.4(d) Actual Closing Date Indebtedness Section 3.4(d) Actual Working Capital Section 3.4(d) Acquisition Transaction Section 7.6(a) Adjusted Merger Consideration Section 3.4(f) Agreement Preamble Biogen Idec License Agreement Assumed Option Recitals Bankruptcy and Equity Exception Section 4.7 Biogen Idec Supply Agreement 4.2 Base Balance Sheet Section 4.7 Books 4.6 Base Merger Consideration Section 3.2(a)(i) Cash, Indebtedness and Records Expenses Schedule Section 2.12(f)(23.1(h) Claim Notice Certificate of Merger Section 8.3(a) 2.2 Closing Section 2.3 Closing Date Section 2.3 Common Stock Section 3.1(b) Company Preamble Company Common Stock Dissenting Shares Section 2.8 3.5 Company Terminating Breach Section 9.1(d) Continuing Employee Section 7.14(a) Deductible Section 10.4(a) DGCL Section 2.1 Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 Employee Benefit Program Section 4.18(a) ERISA Section 4.13(a4.18(a) ERISA Affiliate Escrow Account Section 4.13(a3.3(a) Finally Determined Escrow Agent Section 8.5(b3.3(a) First Milestone Escrow Agreement Section 2.10(e3.3(a) First Milestone Payment Escrow Amount Section 2.10(e3.3(a) Estimated Closing Balance Sheet Section 3.4(a) Estimated Closing Date Cash Section 3.4(a) Estimated Closing Date Indebtedness Section 3.4(a) Estimated Working Capital Section 3.4(a) Excepted Representations Section 10.1 Final Closing Balance Sheet Section 3.4(b) Final Closing Date Cash Section 3.4(b) Final Closing Date Indebtedness Section 3.4(b) Final Working Capital Section 3.4(b) Financial Information Section 4.6 Firm Section 3.4(c) Fundamental Representations Section 10.1 HSR Act Section 4.2 Indemnified Party Section 10.3 Indemnifying Party Section 8.3(a10.3 Initial Merger Consideration Section 3.2(a) Instrument Interim Period Section 2.12(c7.1(a) Investor Restricted Period Section 7.7(b) Investor Restricted Stockholder Section 7.7(b) Losses Section 10.2 Management Restricted Period Section 7.7(b) Management Restricted Stockholder Section 7.7(b) Material Contract Section 4.13 Material Stockholder Preamble Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Parent Preamble Parent Disclosure Net Working Capital Target Section 3.2(a)(iii) November 30, 2007 Unaudited Financials Section 4.6 Objection Notice Section 3.4(c) Other Stockholders Recitals Parachute Payment Waiver Section 7.14(e) Payment Schedule Article V Parent Indemnified Parties Section 8.2(a)(i3.1(g) parties Preamble Payee Preferred Stock Section 8.5 Payor 3.1(b) Privacy Policy Section 8.5 Per Diem Taxes 4.13(d) Released Persons Section 8.7(a7.9 Reserve Account Section 3.2(e) Proceeding Special Representations Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 10.1 Stockholders Recitals Stockholder Stockholders’ Representative Preamble Super Majority Stockholder Indemnified Party Section 2.12(b) 10.3 Stockholder Indemnifying Party Section 10.2 Surviving Corporation Section 2.1 Third Milestone Tax Reduction Section 2.10(g7.11(b) Third Milestone Payment Amount Termination Date Section 2.10(g)9.1(f) Ticketmaster Preamble Ticketmaster Indemnified Party Section 10.2 Ticketmaster Indemnifying Party Section 10.3 Ticketmaster Plans Section 7.14(b) Ticketmaster Shares Section 6.3(a) Ticketmaster Terminating Breach Section 9.1(e) Transactions Section 2.1
Appears in 1 contract
Sources: Merger Agreement (Ticketmaster)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acquisition Proposal Section hereof in which such term is defined: 5.3(g)(i) Agreement Preamble Biogen Idec License Agreement Board Recitals Board Recommendation Section 4.7 Biogen Idec Supply Agreement 3.3(b) Change of Board Recommendation Section 4.7 Books and Records 5.3(a) China JV Section 2.12(f)(2) Claim Notice Section 8.3(a) 5.12 Closing Section 2.3 2.2(a) Closing Date Section 2.3 2.2(a) Closing Date Payment Section 2.2(b) Company Preamble Company Benefit Plan Section 3.14(a) Company Bylaws Section 3.1 Company Charter Section 3.1 Company Common Stock Section 2.8 3.2(a) Company Designees Section 5.18(a) Company Disclosure Schedule Article IV 3 Company Expenses Schedule Financial Statements Section 2.13 3.7(c) Company Indemnified Parties Leased Real Property Section 8.2(a)(ii3.17(a) Contracts Company Material Contract Section 4.8(a3.19 Company Meeting Section 5.4(b) Covered Party (PartiesCompany Options Section 3.2(a) Company Owned Real Property Section 8.2(a)(ii3.17(a) Damages Company Preferred Stock Section 8.2(a)(i3.2(a) Company Real Property Section 3.17(a) Company RSUs Section 3.2(a) Company SEC Documents Section 3.7(a) Company Termination Fee Section 7.3(a) Competing China JV Proposal Section 5.3(h) Confidentiality Agreement Section 5.2(b) DGCL Section 2.1 Document Retention Period 4.7 Dispute Section 2.12(f)(28.8(b) Drug Regulatory Agency ECL Claims Section 4.25 Effective Time 7.4(c) Escrow Agent Section 2.2 ERISA 5.21 Escrow Agreement Section 4.13(a5.21 FCPA Section 3.26 Guarantor Recitals Guarantee Recitals ICDR Section 8.8(b) ERISA Affiliate Intervening Event Section 4.13(a5.3(g)(v) Finally Determined Investor Preamble Investor Designees Section 8.5(b5.18(a) First Milestone Investor Sub Section 2.10(e5.22 Investor Termination Fee Release Event Section 7.4(a) First Milestone Payment Amount Letter of Credit Section 2.10(e5.23 Minority Transaction Termination Fee Section 7.3(a) Indemnifying Party OFAC Section 8.3(a3.27 Outside Date Section 7.1(d) Instrument Section 2.12(c) Merger Per Share Price Section 2.1 Merger Certificate Proposed Changed Terms Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i5.3(d)(ii) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Purchase Price Section 2.1 Third Milestone Service Provider Section 2.10(g3.14(a) Third Milestone Payment Amount Shares Section 2.10(g2.1 Superior Majority Proposal Section 5.3(g)(ii) Superior Minority Proposal Section 5.3(g)(iii) Superior Proposal Section 5.3(g)(iv)
Appears in 1 contract
Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Absence of Legal Restraint Condition Exhibit A Acceptance Time Section 1.1(c) Agreement Preamble Biogen Idec License Alternative Proposal Section 5.4(f) Appraisal Rights Section 2.1(b) Benefits Continuation Period Section 5.5(a) Book-Entry Shares Section 2.2(a) Cancelled Shares Section 2.1(a)(ii) Capex Budget Section 5.1(b)(xvi) Certificate of Merger Section 1.5 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Clean Team Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a5.3(b) Closing Section 2.3 1.4 Closing Date Section 2.3 1.4 Code Section 2.2(b)(iv) Collection Costs Section 7.3(b) Common Stock Recitals Company Preamble Company Common Stock Approvals Section 2.8 3.4 Company Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule Employees Section 2.13 5.5(a) Company Indemnified ESPP Section 3.2(b)(i) Company Recommendation Section 3.3 Company Registered IP Section 3.11(a) Company Related Parties Section 8.2(a)(ii7.3(c) Contracts Company SEC Reports Section 4.8(a3.6(a) Covered Party (PartiesCompany Termination Fee Section 7.3(a) Confidentiality Agreement Section 8.2(a)(ii5.3(b) Damages Continuing Directors Section 8.2(a)(i8.10 Depository Agent Section 2.2(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) DTC Section 2.12(f)(22.2(b)(ii) Drug Regulatory Agency Section 4.25 EDGAR Article 3 Effective Time Section 2.2 ERISA 1.5 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Offering Period Section 4.13(a2.3(c) Finally Determined Existing Loan Documents Section 8.5(b2.4 Fair Value Section 8.14 FCPA Section 3.14(d) First Milestone FDA Application Integrity Policy Section 2.10(e3.16(g) First Milestone Payment Filed SEC Reports Article 3 Indemnified Party Section 5.9(a) Intervening Event Section 5.4(h) Intervening Event Notice Section 5.4(d) Intervening Event Notice Period Section 5.4(d) Leases Section 3.10(a) Legal Restraint Section 6.1(a) Material Contract Section 3.12(a) Maximum Amount Section 2.10(e5.9(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 2.1(a)(i) Minimum Tender Condition Exhibit A New Plans Section 2.2 Merger Sub Preamble 5.5(b) Offer Recitals Offer Conditions Section 1.1(b) Offer Documents Section 1.1(e) Old Plans Section 5.5(b) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(c) parties Preamble Payee Paying Agent Section 8.5 Payor 2.2(a) Payment Fund Section 8.5 Per Diem Taxes Section 8.7(a2.2(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Payoff Amount Section 2.10(f2.4 Payoff Letter Section 2.4 PMA Section 3.16(e) Stockholder Consent Regulatory Condition Exhibit A Remedy Action Section 5.6(a) Representatives Section 5.3(a) Schedule 14D-9 Section 1.2(b) Security Incident Section 3.11(i) Share Recitals Stockholder Representative Preamble Super Majority Superior Proposal Section 2.12(b5.4(g) Superior Proposal Notice Section 5.4(c) Superior Proposal Notice Period Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.21 Termination Condition Exhibit A Termination Date Section 5.1(a) Third Milestone Payment Amount Trade Authorizations Section 2.10(g3.14(f)
Appears in 1 contract
Sources: Merger Agreement (Stryker Corp)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Action Section 4.12 Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 6.4(b) Alternative Acquisition Agreement Section 6.4(c)(2) Alternative Financing Section 6.6 Agreement Preamble Biogen Idec License Agreement Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Cashed-Out Option Section 2.12(f)(23.1(f)(ii) Claim Notice Cayman Companies Law Preamble Certificates Section 8.3(a3.2(c) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(b)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(e)(i) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(f) D&O Insurance Section 6.12(b) Dissenter Rights Section 3.1(e) Dissenting Shares Section 3.1(e) Dissenting Shareholders Section 3.1(e) Effective Time Section 2.3 Equity Commitment Letters Section 5.6 Equity Financing Section 5.6 Equity Financing Commitments Section 5.6 End Date Section 8.1(b)(i) Exchange Fund Financing Financing Commitments Section 3.2(b) Section 5.6(a) Section 5.6(a) Guarantor Preamble HKIAC Section 9.7(c) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Independent Committee Preamble Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Parent Material Adverse Effect Section 8.2(e)(i) Section 5.4(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Services Provider Section 4.14(g) Support Agreement Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Company Transactions Section 2.1 Third Milestone Preamble Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Agreement Preamble Biogen Idec License Agreement of Merger Section 4.7 Biogen Idec Supply Agreement 1.2 Audited Financial Statements Section 4.7 Books and Records 3.7(a) Cashed-Out Shares Section 2.12(f)(28.5(a) Certificates Section 2.3(a) CGCL Recitals Claim Notice Section 8.3(a8.4(a) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Company Preamble Company Benefit Plan Section 3.9(a) Company Common Stock Section 2.8 2.1(a) Company Customers Section 3.21 Company Disclosure Schedule Article IV III Company Expenses Schedule Financial Statements Section 2.13 3.7(a) Company Material Contracts Section 3.11(a) Company Material Intellectual Property Section 3.15 Company Permits Section 3.6 Company Subsidiary Section 5.14 Confidentiality Agreement Section 5.5 Consents Section 3.5(c) DNS Korea Financial Statements Section 3.7(a) Effective Time Section 1.2 Escrowed Shares Section 2.2 FCPA Section 3.6(d) Financial Statements Section 3.7(a) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e8.3(c) Indemnifying Party Section 8.3(a8.4(a) Instrument Losses Section 2.12(c8.2 Merger Recitals Merger Consideration Section 2.1(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Multiemployer Plan Section 3.9(c) Outside Date Section 7.1(b) Parent Preamble Parent Balance Sheet Section 4.8(c) Parent Benefit Plan Section 4.10(a) Parent Board Section 1.7 Parent Customers Section 4.19 Parent Disclosure Schedule Article V IV Parent Financial Advisor Section 4.23 Parent Indemnified Parties Section 8.2(a)(i8.2(a) parties Parent Material Contract Section 4.12 Parent Material Intellectual Property Section 4.16 Parent Options Section 4.3(a) Parent Permits Section 4.7(a) Parent Preferred Stock Section 4.3(a) Parent SEC Filings Section 4.8(a) Parent Recommendation Section 5.6(d) Parent Stockholder Approval Section 4.5 Parent Stockholders’ Meeting Section 5.6(c) Parties Preamble Payee Pending Claim Section 8.5 Payor 8.5(b) Proxy Statement Section 8.5 Per Diem Taxes 5.6(a) Remedies Exception Section 8.7(a3.4(a) Proceeding Restructuring Plan Section 4.17 Royalties 5.13 ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 2.10(h4.8(d) Second Milestone Special Committee Section 2.10(f) Second Milestone Payment Amount Section 2.10(f8.8(a) Stockholder Consent Recitals Preamble Stockholder Representative Preamble Super Majority Indemnified Parties Section 2.12(b8.2(b) Surviving Corporation Section 2.1 Third Milestone 1.1 Tax Matter Section 2.10(g5.11(d) Termination Fee Section 7.2(d) Third Milestone Payment Amount Party Claim Section 2.10(g8.4(a) Transfer Taxes Section 5.11(f)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below. Location of AAA Section hereof in which such term is defined: 12.5(c) Affiliates Section 7.17 Agreement Preamble Biogen Idec License Agreement of Merger Section 2.3 ▇▇▇▇▇▇ Employment Agreement Section 4.7 Biogen Idec Supply Agreement 11.3(w) Basket Section 4.7 Books and Records 12.2(c)(i) CCC Recital B CERCLA Section 2.12(f)(2) Claim Notice Section 8.3(a12.2(c)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Closing Date Severance Working Capital Section 3.11(a) Closing Date Working Capital Section 3.3(a) COBRA Section 7.14(e) Company Preamble Company 401(K) Plan Section 10.7(d) Company Board Recommendation Section 7.3(a) Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Recital A Company Indemnified Parties Section 8.2(a)(ii12.2(b) Contracts Company Indemnified Party Section 4.8(a12.2(b) Covered Company Indemnifying Parties Section 12.2(a) Company Indemnifying Party (PartiesSection 12.2(a) Contingent Purchase Price Payment Section 8.2(a)(ii3.4(d) CTS Section 11.3(v) Customers Section 7.11(a) Damage Payment Section 12.2(d) Damages Section 8.2(a)(i12.2(a) DGCL Determination Date Section 2.1 Document Retention Period 3.3(b) Disclosure Letter Article VII Dispute Notice Section 2.12(f)(23.4(b) Drug Regulatory Agency Dissenting Shareholder Section 4.25 3.6(a) Dissenting Shares Section 3.6(a) Effective Time Section 2.2 2.3 Environmental Law Section 7.18 ERISA Section 4.13(a7.14(a) ERISA Affiliate Section 4.13(a7.14(a) Finally Determined Escrow Section 8.5(b3.7(a) Escrow Agreement Section 3.7(a) Estimated Severance Working Capital Section 3.10 Estimated Severance Working Capital Statement Section 3.10 Estimated Working Capital Section 3.2 Estimated Working Capital Statement Section 3.2 Excess Payments Section 3.6(d) Expenses Section 10.6 Final Net Sales Statement Section 3.4(c) First Milestone Release Date Section 2.10(e3.7(a)(i) First Milestone Payment Amount GAAP Section 2.10(e7.4(b) Indemnifying Party Governmental Entity Section 8.3(a7.3(b) Instrument Hazardous Substance Section 2.12(c7.18 Insurance Policies Section 9.1 Intellectual Property Rights Section 7.19(a) Interim Balance Sheet Section 7.4(a) Interim Financial Statements Section 7.4(a) KLO Preamble KLO Agreement of Merger Section 2.1 4.3 KLO Board Recommendation Section 7.3(a) KLO Dissenting Shareholder Section 4.9(a) KLO Dissenting Shares Section 4.9(a) KLO Excess Payments Section 4.9(d) KLO Merger Certificate Recital D KLO Merger Effective Time Section 2.2 4.3 KLO Merger Sub Preamble KLO Required Shareholder Vote Section 7.12 KLO Surviving Entity Section 4.1 Liens Section 7.2(f) Material Agreement Section 7.13(a) Merger Recital B Merger Sub Preamble MT Recital E MT Payment Date Section 5.2(b) MT Purchase Agreement Section 5.1 MT Purchase Price Section 5.2(a) MT Stock Section 5.1 Net Sales Statement Section 3.4(a) Notice Section 12.3(a) Notice of Set-Off Dispute Section 3.5 Objection Notice Section 12.3(c) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i12.2(a) parties Preamble Payee Parent Indemnified Party Section 8.5 Payor 12.2(a) Parent Indemnifying Parties Section 8.5 Per Diem 12.2(b) Parent Indemnifying Party Section 12.2(b) Parent Objection Notice Section 12.3(d) Percentage of Contingent Purchase Price Payment Section 3.4(d) Permits Section 7.8(a) Post-Closing Tax Period Section 9.2(d) Pre-Closing Return Section 9.2(d) Real Property Section 7.16(a) Required Shareholder Vote Section 7.12 Second Release Date Section 3.7(a)(ii) Seller Representative Letter Section 3.8(g) Selling Entity Employees Section 7.20(b) Set-Off Notice Section 3.5 Set-Off Review Period Section 3.5 Severance Working Capital Statement Section 3.11(a) Straddle Period Section 12.2(a)(vi) Surviving Entity Section 2.1 Tax Contest Section 9.2(d) Third Party Claim Section 12.4(a) Third Party Notice Section 12.4(a) Transfer Taxes Section 8.7(a9.2(e) Proceeding Violation Section 4.17 Royalties 7.3(c) Working Capital Statement Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.3(a)
Appears in 1 contract
Sources: Purchase Agreement (Oakley Inc)
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 2004 Plan Section hereof in which such term is defined: 2.4 2009 Plan Section 2.4 Acceptance Time Section 1.1(b) Agreement Preamble Biogen Idec License Agreement Annex I Section 4.7 Biogen Idec Supply Agreement 1.1(a) ARRA Section 4.7 Books and Records 3.14(k) Balance Sheet Section 2.12(f)(23.9(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(b) Breakup Fee Section 7.3(b) Certificate of Merger Section 1.5 Certificates Section 2.2(b) Change of Board Recommendation Section 5.4(b) Closing Section 2.3 1.5 Closing Date Section 2.3 1.5 COBRA Section 3.14(k) Company Preamble Company Board Recitals Company Board Recommendation Recitals Company Bylaws Section 3.2 Company Charter Section 3.2 Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Preamble to Article IV III Company Expenses Schedule Representatives Section 2.13 5.3(a) Company Securities Section 3.3(a) Company Stockholder Approval Section 3.4(b) Comparable Carrier Section 5.16 Continuing Directors Section 1.3(b) DGCL Recitals Dissenting Shares Section 2.3 DOJ Section 5.8 D&O Insurance Section 5.16 Effective Time Section 1.5 Equivalent Coverage Section 5.16 ERISA Affiliate Section 3.14(a) Exchange Act Section 1.1(a) Expiration Date Section 1.1(d) Financial Advisor Section 3.22 FTC Section 5.8 Go-Shop Party Section 5.4(b) Go-Shop Period Termination Date Section 5.4(a) Holding Company Recitals Indemnification Agreements Section 5.16 Indemnified Parties Section 8.2(a)(ii5.16 Initial Expiration Date Section 1.1(d) Insurance Policies Section 3.20 Insured Persons Section 5.16 IP Contracts Section 4.8(a3.19(e) Covered Party (PartiesLeased Real Property Section 3.16(b) Material Contracts Section 8.2(a)(ii3.13(a) Damages Material Leased Real Property Section 8.2(a)(i3.16(b) DGCL Material Real Property Leases Section 2.1 Document Retention Period Section 2.12(f)(23.16(d) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.16
Appears in 1 contract
Sources: Merger Agreement (Azz Inc)
Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Accelerated Options Section 2.12(a) Acquisition Sub Preamble Affected Employees Section 6.9 Agreement Preamble Biogen Idec License Agreement Amended Severance Policy Section 4.7 Biogen Idec Supply Agreement 6.9 BRINC Preamble BRLLC Preamble BRLLC Expenses Section 4.7 Books and Records 2.10(a) Certificate of Merger Section 2.12(f)(22.3 Change of Control Payment Statement Section 2.10(c) Change of Control Payments Section 2.10(c) Claim Notice Section 8.3(a10.4(a) Closing Section 2.3 2.4(a) Closing Date Section 2.3 Company Preamble Company Common Stock 2.4(a) Closing Working Capital Section 2.8 Company 2.14(a)(i) Confidential Information Section 6.5(a)(i) Copyright Office Section 6.16(b) Customer Information Section 3.16 D&O Tail Section 6.19(b) Damages Section 10.2(a) Decline Date Section 2.14(e) Delivering Party Section 6.5(a)(ii) DGCL Recitals Disclosure Schedule Article IV Company Expenses Schedule III Dispute Notice Section 2.13 Company 10.4(b) Disputed Line Items Section 2.14(e) Dissenting Shares Section 2.16(a) Dissenting Shares Reduction Amount Section 2.16(b) DOJ Section 6.6 Effective Time Section 2.3 Environmental Costs Section 3.14(c)(ii) Equityholder Indemnified Parties Section 8.2(a)(ii10.2(b) Estimated Working Capital Section 2.14(b) Estimated Working Capital Deficiency Section 2.14(c) EU Personal Data Section 5.8 Excess Negative Adjustment Amount Section 2.14(g) Expense Statement Section 2.10(a) Final Tax Returns Section 9.2(a)(i) Form Working Capital Statement Section 2.14(a)(i) FTC Section 6.6 Fundamental Representation Distributions Section 10.2(d) Funded Indebtedness Statement Section 2.10(d) Gannett Preamble General Survival Date Section 10.1 Indemnified Executive Section 6.19(a) Indemnity Escrow Amount Shortfall Section 2.14(g) Information Statement Section 6.3(a) Initial Calculation Section 2.14(d) Insolvent Section 5.6 Kenexa Indemnified Parties Section 10.2(a) Kenexa Technology Preamble Labor Union Section 3.11(a)(i) Letter of Transmittal Section 2.11(b) Material Client Contract Section 3.10(a)(i) Material Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c3.10(a) Merger Section 2.1 Merger Certificate 2.2 Negative Adjustment Amount Section 2.2 Merger Sub Preamble 2.14(f) Notice of Disagreement Section 2.14(e) Off-the-Shelf Software Section 3.15(c) Organizational Documents Section 2.4(c)(ii) Outside Date Section 8.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Positive Adjustment Amount Section 2.10(f2.14(f) Stockholder Consent Recitals Stockholder Post Preamble Privacy Policy Section 3.16 Qualified Plan Section 3.11(b)(ii)(I) Receiving Party Section 6.5(a)(iii) Registered Intellectual Property Section 3.15(e) Regulatory Agreements Section 3.25(b) Relevant Group Section 3.13(a)(i) Representative Preamble Super Majority Required Exchange Documents Section 2.12(b2.11(b) Requisite BRINC Vote Section 3.3(b) Safe Harbor Section 5.8 Selling Members Recitals Settlement Accountants Section 2.14(e) Severance Payment Statement Section 2.10(b) Severance Payments Section 2.10(b) Straddle Periods Section 9.2(a)(ii) Surviving Corporation Section 2.2 Takeover Statutes Section 3.25(a)(iii) Tax or Taxes Section 3.13(a)(ii) Tax Return Section 3.13(a)(iii) Terminated Plan Section 3.11(b)(i) Transactions Section 2.4(a) Transfer Section 2.1 Third Milestone Transfer Taxes Section 2.10(g3.13(a)(iv) Third Milestone Payment Amount Tribune Preamble USPTO Section 2.10(g6.16(b) WARN Act Section 3.11(a)(i)
Appears in 1 contract
Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.01(e) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 8.09(b) Alternative Financing Documents Section 4.7 Books and Records 8.09(b) Arbitrator Section 2.12(f)(211.08(b) Claim Notice Base Premium Section 8.3(a8.04(d) Change in the Company Recommendation Section 7.02(b) Closing Section 2.3 3.02 Closing Date Section 2.3 3.02 Company Preamble Company Common Stock Board Recitals Company Board Actions Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 5.02(a) Company Disclosure Schedule Article IV Group Section 10.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 10.02(b) Competing Proposal Section 8.2(a)(ii7.02(d) Contracts Competition Laws Section 4.8(a5.05 Covered Persons Section 8.04(a) Covered Party (PartiesDebt Commitment Letter Section 6.05(a) Debt Financing Source Section 8.2(a)(ii6.05(a) Damages Deposit Agreement Section 8.2(a)(i) DGCL 4.05 Depositary Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 4.05 Effective Time Section 2.2 ERISA 3.03 Enforceability Exceptions Section 4.13(a5.03(a) ERISA Affiliate Expiration Time Section 4.13(a2.01(c)(ii)(B) Finally Determined Financing Section 8.5(b6.05(a) First Milestone Financing Condition Annex A Financing Document Section 2.10(e8.09(b) First Milestone Payment Amount GAAP Section 2.10(e5.06(b) Indemnifying Party Governmental Entity Section 8.3(a5.05 HKIAC Section 11.08(b) Instrument HKIAC Rules Section 2.12(c11.08(b) Indemnification Agreements Section 8.04(a) Intervening Event Section 7.02(g) Intervening Event Termination Section 7.02(g) Legal Proceeding Section 6.06 ▇▇▇ Preamble Merger Recitals Merger Consideration Section 2.1 Merger Certificate 4.02(a) Minimum Condition Annex A Non-Required Remedy Section 2.2 Merger Sub Preamble 8.02(e) Offer Recitals Offer Conditions 2.01(a) Offer Documents Section 2.01(f) Offer Price Recitals Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Termination Fee Section 10.02(c) Parties Preamble Party Preamble Paying Agent Section 8.2(a)(i4.02(a) parties Preamble Payee Payment Fund Section 8.5 Payor 4.02(a) Per ADS Merger Consideration Section 8.5 4.01(b) Per Diem Taxes Share Merger Consideration Section 8.7(a4.01(a) Proceeding Plan of Merger Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment 3.03 Required Amount Section 2.10(f6.05(c) Stockholder Consent ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 5.06(a) Schedule TO Section 2.01(f) Schedule 13E-3 Section 2.02(b) Schedule 14D-9 Section 2.02(b) SEC Documents Section 5.06(a) Securities Act Section 5.06(a) Share Certificates Section 4.02(b)(i) Special Committee Recitals Stockholder Representative Special Committee Recommendation Recitals Super ROI Preamble Super Majority ROI Group Section 2.12(b10.02(d) Superior Proposal Section 7.02(f) Surviving Corporation Company Section 2.1 Third Milestone 3.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 8.05 Transaction Litigation Section 2.10(g8.07 Transactions Recitals Uncertificated Shares Section 4.02(b)(i)
Appears in 1 contract